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Maternal hyperglycemia is a common condition with a profound effect on prenatal and maternal 
health. We used two complementing cohorts to estimate the associations between: 1) gestational 
weight gain (GWG), adiposity distribution, and maternal hyperglycemia; 2) pre-pregnancy body 
mass index (BMI) and an array of maternal nutritional biomarkers; and 3) maternal vitamin D 
status and maternal hyperglycemia. In the Study of Nutrition and Pregnancy (SNAP), biceps and 
triceps skinfolds and waist circumference were measured at <13 weeks gestation and 25-
hydroxyvitamin D [25(OH)D] concentrations were measured at <16 weeks gestation. Serial 
weight measurements and post-load glucose concentrations were abstracted from medical 
records. Because a full array of nutritional biomarkers was not available in SNAP, we also used 
the Antidepressant Use During Pregnancy (ADUP) study. In ADUP, height and nutritional 
biomarkers were measured and pre-pregnancy weight was self-reported at ≤ 20 weeks gestation. 
In the SNAP study, each 0.3-kg/week increase in first trimester GWG rate was associated with a 
2.2 (95% CI: 0.1, 4.3)-mg/dl increase in glucose concentration. Each 8.6-mm increase in biceps 
skinfold thickness and 11.7-mm increase in triceps skinfold thickness was associated with 4.3 
(95% CI: 0.2, 8.5)-mg/dl increases in glucose. In the ADUP study, principal component analysis 
of the biomarkers resulted in an EFA component, a Micronutrient component, and a Carotenoid 
component. Obese pregnant women were 3.0 (95% CI: 1.1, 7.7) times as likely of being in the 
lowest tertile of the EFA component and 4.5 (95% CI: 1.7, 12.3) times as likely of being in the 
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lowest tertile of the Carotenoid component as their lean counterparts. Among non-smokers in 
SNAP, each 21-nmol/L increase in serum 25(OH)D was associated with a 4.1 (95% CI: 0.9, 7.2)-
mg/dl increase in maternal post-load glucose concentration. Among smokers, each 21-nmol/L 
increase in serum 25(OH)D was associated with a 7.3-(95% CI: 11.4, 3.1) mg/dl decrease in 
maternal glucose concentration after confounder adjustment. This dissertation is important to 
public health because hyperglycemia has a major impact on the health of mothers and infants and 
these data may lead to nutritional interventions that are safe, inexpensive, and acceptable to 
women. 
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1.0  INTRODUCTION 
1.1 BACKGROUND 
Maternal hyperglycemia is a common complication of pregnancy with profound effects on the 
health of mothers and children. It is defined as high blood sugar during pregnancy and, when 
above a certain threshold, is a defining component of gestational diabetes mellitus (GDM). Rates 
of hyperglycemia during pregnancy are not well established, but it is estimated that as many as 
4% of pregnancies are complicated by GDM (Getahun, Nath, Ananth, Chavez, & Smulian, 
2008). GDM has long been associated with poor pregnancy outcomes ranging from cesarean 
delivery to infant macrosomia (Henriksen, 2008; Jevitt, 2005). Evidence suggests that there is a 
dose response relationship between maternal glucose concentrations and adverse pregnancy 
outcomes, even below the threshold of overt GDM (Metzger et al., 2008). Despite this, few 
studies have examined glucose concentrations as a continuous outcome. Studies are needed to 
better understand the risk factors that contribute to high glucose concentrations during 
pregnancy.   
Current evidence suggests that maternal obesity, most commonly measured by pre-
pregnancy body mass index (BMI), is one of the strongest modifiable risk factors for GDM (Chu 
et al., 2007). But pre-pregnancy BMI only describes one aspect of maternal adiposity. Other 
measures of maternal adiposity, such as gestational weight gain (GWG) (Hedderson, Gunderson, 
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& Ferrara, 2010; Herring et al., 2009; Saldana, Siega-Riz, Adair, & Suchindran, 2006; Tovar, 
Must, Bermudez, Hyatt, & Chasan-Taber, 2009), subcutaneous fat (Yilmaz, Kucuk, Ilgin, & 
Dagdelen, 2010) and central adiposity (Branchtein et al., 1997; Madhavan, Beena Kumari, & 
Sanal, 2008; Wendland, Duncan, Mengue, Nucci, & Schmidt, 2007; Yeung et al., 2010; S. 
Zhang, Folsom, Flack, & Liu, 1995), may be associated with maternal glucose concentrations, 
but have been less well researched. These measures can be easily calculated during pregnancy 
from basic anthropomorphic measurements and, when used with pre-pregnancy BMI, have the 
potential to provide a better assessment of a woman’s risk for hyperglycemia during pregnancy. 
An important link in the relationship between maternal adiposity and GDM is nutrient 
deficiency. Obese pregnant women may be more likely to be deficient in the nutrients that 
impact glucose metabolism, such as antioxidants, folate, essential fatty acids (EFA) and vitamin 
D. Previous literature suggests that obese patients may be more likely to have poor nutritional 
status (Andersen et al., 2006; Bodnar, Catov, Roberts, & Simhan, 2007; Karlsson et al., 2006; 
Kimmons, Blanck, Tohill, Zhang, & Khan, 2006), but this has not been well studied in 
pregnancy. Vitamin D in particular may have a substantial biological effect on glucose 
homeostasis (C. Zhang et al., 2008). However, the relationship between vitamin D and maternal 
glucose tolerance has not been extensively researched.  
Exploring the interplay between maternal obesity, nutrient deficiencies and glucose 
intolerance in pregnancy is significant because nutrition is a modifiable risk factor. Given that 
GDM has a major impact on the health and well-being of mothers and infants, these data may 
lead to nutrition interventions to prevent GDM that are safe, inexpensive, and acceptable to 
women. 
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1.2 RESEARCH AIMS 
The goal of this dissertation was to explore the interrelationship among maternal adiposity, 
micronutrient and EFA status, and glucose concentrations during pregnancy. We used data from 
two prospective cohort studies. The Study of Nutrition and Pregnancy (SNAP) was a large, 
prospective pregnancy cohort study with rigorous data on maternal adiposity, vitamin D, and 
glucose concentrations. The Antidepressant Use during Pregnancy (ADUP) Study was a smaller 
cohort with data on pre-pregnancy BMI and a full panel of maternal nutritional biomarkers. The 
two studies complemented one another to provide novel data on maternal obesity, nutrition and 
hyperglycemia. 
The specific aims of this project were as follows: 
1) Determine the independent and joint associations between maternal pre-pregnancy 
BMI, GWG, and adiposity distribution at <16 weeks gestation and maternal post-load glucose 
concentrations. 
2) Use principal component analysis to discover the underlying structure of maternal 
nutritional biomarkers and evaluate the independent association between general adiposity and 
these patterns at ≤ 20 weeks gestation. 
3) Determine the association between maternal vitamin D status at <16 weeks gestation 
and maternal post-load glucose concentrations. 
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2.0  LITERATURE REVIEW 
Maternal hyperglycemia, or high blood sugar during pregnancy, is a defining component of 
GDM. Although maternal hyperglycemia below the threshold of GDM diagnosis exhibits a dose-
response association with adverse birth outcomes such as primary cesarean delivery, high birth 
weight, neonatal hypoglycemia, preeclampsia, and shoulder dystocia (Metzger, et al., 2008), very 
little research has been done on this clinically important outcome. Research in the arena of 
maternal glucose concentrations has largely focused on GDM, which is defined as glucose 
intolerance, i.e. the inability to appropriately metabolize sugars, with onset or first recognition 
during pregnancy, as an outcome. For example, rates of hyperglycemia during pregnancy are not 
well established, but it is estimated that GDM occurs in 4% of pregnancies (Getahun, et al., 
2008). GDM has been found to be associated with short- and long-term health consequences in 
both mother and infant. GDM is a major risk factor for stillbirth, infant overgrowth (Henriksen, 
2008), shoulder dystocia, cesarean delivery, and neonatal hypoglycemia (Jevitt, 2005). GDM can 
also affect both mother and child later in life. Between 15% and 60% of women with gestational 
diabetes will develop type 2 diabetes five to 15 years after delivery (C. Kim, Newton, & Knopp, 
2002). It is estimated that large for gestational age infants born to mothers with GDM are at an 
almost four times greater risk of developing metabolic disorder (including glucose intolerance) 
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by the age of eleven than infants born to mothers without GDM (Boney, Verma, Tucker, & 
Vohr, 2005).  
2.1 INTRODUCTION 
Although the etiology of hyperglycemia during pregnancy is still largely unknown, the etiology 
of GDM is estimated to be similar to the etiology of type 2 diabetes mellitus (Robitaille & Grant, 
2008; Solomon et al., 1997). The etiology and pathophysiology of type 2 diabetes can be 
different among patients, but ultimately manifests in dysfunction of the insulin producing cells in 
the pancreas (β-cells) and/or insulin resistance in tissue. The possible mechanisms linking 
obesity to type 2 diabetes are complex. Excess fat can cause high concentrations of free fatty 
acids, altered adipokine expression, and low-grade inflammation, all of which are thought to 
increase insulin resistance and the secretion of insulin by β-cells (Ioannidis, 2008). It is strongly 
suggested that obesity plays a key role in the development of type 2 diabetes (Anderson, 
Kendall, & Jenkins, 2003). There is some evidence to suggest that similar mechanisms occur in 
the development of GDM (Klein et al., 2008; Sivan & Boden, 2003; Tsai et al., 2005). Increased 
insulin resistance is a normal physiological change during pregnancy and is thought to be a 
mechanism to nourish the fetus. In a normal third trimester, a mother’s insulin sensitivity has 
decreased to 30% that of her pre-pregnant state (Buchanan & Xiang, 2005). Maternal adiposity 
may be a factor that explains how normal insulin resistance during pregnancy can develop to 
maternal hyperglycemia and GDM. The goal of this project was to explore the interrelationships 
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among maternal adiposity, micronutrient and EFA status, and glucose concentrations during 
pregnancy (Figure 1). 
 
 
Figure 1. Proposed interrelationship between maternal adiposity, nutrition, and maternal hyperglycemia. 
2.2 MATERNAL GLUCOSE CONCENTRATIONS AND ADIPOSITY 
2.2.1 Pre-pregnancy body mass index 
The strongest known modifiable risk factor for GDM is maternal pre-pregnancy BMI. In the 
United States, the rate of GDM is increasing in parallel with an epidemic rise in pre-pregnancy 
obesity for both black and white women (Getahun, et al., 2008; S. Y. Kim, Dietz, England, 
Morrow, & Callaghan, 2007) (Figure 2). 
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Figure 2. Increasing prevalence of pre-pregnancy obesity (S. Y. Kim, et al., 2007) and gestational diabetes 
(Getahun, et al., 2008), by race 
 
The relationship between pre-pregnancy BMI, the most common measurement of 
maternal general adiposity, and GDM has been extensively researched in a variety of populations 
(Haeri, Guichard, Baker, Saddlemire, & Boggess, 2009; Hedderson, Williams, Holt, Weiss, & 
Ferrara, 2008; Joy, Istwan, Rhea, Desch, & Stanziano, 2009; Knight, Kurinczuk, Spark, & 
Brocklehurst, 2010; Leung et al., 2008; Nohr et al., 2009; Qvigstad, Voldner, Godang, 
Henriksen, & Bollerslev, 2010; Shirazian et al., 2009; Torloni et al., 2009; van Leeuwen et al., 
2010). For example, a meta-analysis of 20 cohort studies estimated that the odds ratios for 
developing GDM were 2.1 (95% CI: 1.8-2.5), 3.6 (95% CI: 3.1-4.2), and 8.6 (95% CI: 5.1-16.0) 
among pre-pregnancy overweight, obese and severely obese women, respectively, compared 
with normal-weight women (Chu, et al., 2007). Researchers have recently looked beyond a 
woman’s weight immediately before pregnancy and have begun to explore the relationship 
between a woman’s weight changes over her life course and her risk of GDM. These studies 
suggest two intriguing new facets in the relationship between a woman’s weight and her risk for 
GDM. Firstly, that women with low birth weight are at increased risk for later development of 
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GDM, and secondly that there is a J-shaped relationship between BMI in early adulthood and 
GDM (Rudra, Sorensen, Leisenring, Dashow, & Williams, 2007; Yeung, et al., 2010). This new 
evidence suggests that the relationship between adiposity and GDM is perhaps more complicated 
than simply higher BMI leads to higher risk for GDM. 
Although the associations between pre-pregnancy BMI and GDM are strong and 
consistent, BMI has limitations as a measure of adiposity. BMI alone has poor sensitivity (49%, 
95% CI: 48-50%) to measure adiposity in women in the adult general population (Romero-
Corral et al., 2008) and cannot be measured during pregnancy. Although a woman may enter 
pregnancy with a healthy pre-pregnancy BMI, she may still excessively gain weight during the 
prenantal period. Additionally, pre-pregnancy BMI only measures general adiposity, and women 
with similar BMI values may have widely varying distribution of adipose tissue. Other measures, 
for example GWG and other anthropometrics, may provide valuable insight to the effect of 
maternal adiposity on glucose concentrations. 
2.2.2 Gestational weight gain 
GWG is the result of the different components of pregnancy, including the fetus and placenta, 
fluid, uterus, mammary glands and fat. Fat mass accumulation increases in parallel with GWG as 
a pregnancy progresses (Rasmussen, Yaktine, & Institute of Medicine (U.S.). Committee to 
Reexamine IOM Pregnancy Weight Guidelines., 2009). Despite our increasing knowledge of the 
physiological effect of fat mass accumulation on insulin resistance during pregnancy (Harlev & 
Wiznitzer, 2010), few studies have quantified the effect of weight gain during pregnancy on the 
risk of GDM. Additionally, pre-pregnancy BMI has an inverse relationship with GWG 
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(Rasmussen, et al., 2009), but it is unknown what role it may play in the relationship between 
GWG and GDM. A cohort study of black and white women found that adequacy of GWG ratio 
(observed/expected) had a borderline association with impaired glucose tolerance only among 
overweight women [OR=2.4, 95% CI: 0.9-6.2, p-value<0.1] and had no association with GDM 
(Saldana, et al., 2006). Among a Hispanic cohort of women, there was a statistically significant 
interaction between pre-pregnancy BMI and GWG in relation to abnormal glucose tolerance (50-
g glucose tolerance test ≥ 135 mg/dl). Once accounting for this interaction, women with a pre-
pregnancy BMI ≥ 35 who had a high rate of weight gain (>0.30 kg/week) were three times as 
likely to develop GDM as women with normal weight gain (Tovar, et al., 2009). Among a 
primarily white population, women in the highest quartile of GWG before GDM screening had 
increased odds of impaired glucose tolerance in pregnancy [OR=2.5, 95% CI: 1.3-5.2], but not 
GDM [OR=0.9, 95% CI: 0.5-1.7] compared to women in the lowest quartile. Pre-pregnancy BMI 
was not found to be a significant effect modifier (Herring, et al., 2009). A recent study found a 
dose response between tertiles of rate of GWG and GDM, and a significant association between 
exceeding the Institute of Medicine’s (IOM) recommended weight guidelines and GDM 
[OR=1.5, 95% CI: 1.1-2.2]. This same study also found that pre-pregnancy BMI was not a 
significant effect modifier, and additionally suggested that risk of GDM was primarily attributed 
to increased weight gain in the first trimester (Hedderson, et al., 2010).  
Randomized controlled trials that assessed the effect of weight control interventions on 
maternal glucose are inconsistent in their conclusions. An evaluation of these studies is further 
complicated because the interventions involved can be separated into dietary, exercise or both 
programs and within these categories, the interventions are widely varied. A meta-analysis of 
nineteen studies concluded that dietary counseling reduced the incidence of GDM, but that the 
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quality of these studies was poor and further research was needed to understand what 
interventions are most effective (Oostdam, van Poppel, Wouters, & van Mechelen, 2011). The 
interventions included dietary, exercise and Metformin treatment. While many interventions may 
be time intensive and expensive, which reduces their real-world feasibility, others are less 
expensive and easier to implement in a clinical setting. For example, Quinlivan et al. found that 
obese pregnant women who were randomized to a four step intervention which included 1) 
provider continuity; 2) weighing at each visit; 3) a five minute intervention by a food 
technologist; and 4) clinical psychology management had lower GWG (7.0 versus 13.8 kg, p < 
0.01) and were less likely to develop GDM (OR = 0.17, 95% CI: 0.03-0.95, p = 0.04) than obese 
controls who received standard care (Quinlivan, Lam, & Fisher, 2011). These studies suggest 
that GWG is a modifiable risk factor and that maternal glucose can be reduced through weight 
management interventions, but further research is needed to develop effective interventions. 
Studies have found differing relationships between GWG and glucose tolerance. 
Additionally, there is not agreement in previously published literature on the role that pre-
pregnancy BMI plays in this relationship. These differences may be partially accounted for by 
the different racial make-ups of the studies and the variety of methods used to measure weight 
gain and glucose tolerance. The Institute of Medicine (IOM) has recently released new 
guidelines for the amount of weight a woman should gain during pregnancy, based on her pre-
pregnancy BMI (Rasmussen, et al., 2009). Only one previous study (Hedderson, et al., 2010) 
explored whether women who exceeded these guidelines were at increased risk for developing 
GDM. Continuous glucose tolerance has not been rigorously studied and only two studies 
examined patterns of weight gain across trimesters of pregnancy (Hedderson, et al., 2010; 
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Herring, et al., 2009), therefore we are unable to fully understand the nature of the relationship 
between GWG and glucose tolerance. Our study aims to fill this gap in knowledge. 
2.2.3 Maternal adiposity distribution 
Studies of type 2 diabetes suggest that adiposity distribution, in particular central obesity, may 
predict insulin resistance in non-pregnant populations better than BMI (Fujimoto, Abbate, Kahn, 
Hokanson, & Brunzell, 1994; Huxley et al., 2008; Nyamdorj et al., 2009). For example, in a 
group of Japanese men, BMI was not related to the insulin sensitivity index, but central 
adiposity, specifically intra-abdominal adiposity, was significantly correlated (Fujimoto, et al., 
1994). But the distribution of body fat in pregnant women has, for the most part, been neglected 
(McCarthy, Strauss, Walker, & Permezel, 2004). 
Anthropometric measurements could potentially be used to describe maternal adiposity 
distribution. Anthropometry can be used to measure general adiposity, central adiposity and 
subcutaneous fat. These can be measured using a variety of techniques, ranging from the very 
technical, for example dual energy X-ray absorptiometry (DEXA) scans, to the very simple, for 
instance height, weight, waist circumference, and bicep and triceps skin folds. Anthropometric 
measurements such as height, weight, waist circumference, and bicep and triceps skin folds are 
inexpensive, objective, noninvasive, and safe. Anthropometric equations, i.e. models of body fat 
based on many different measurements, are predictors of body fat during pregnancy (Paxton et 
al., 1998) and there is evidence that anthropometric measurements can be predictive of perinatal 
outcomes (McCarthy, et al., 2004). 
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Anthropometric measurements may be a good predictor of glucose intolerance in 
pregnancy (Figure 3). BMI has been widely studied as a predictor of GDM, but other 
measurements of maternal adiposity have not been researched as rigorously. The few studies 
available suggest that there is a potential association between GDM and other measures of 
maternal adiposity, such as waist circumference and skin fold thicknesses. 
 
 
Figure 3. Proposed relationship between maternal adiposity (as measured by gestational weight gain and 
adiposity distribution) and maternal hyperglycemia. 
 
Evidence suggests that maternal waist circumference measurements in early pregnancy 
are associated with GDM diagnosis, but there is insufficient evidence to understand the 
temporality, magnitude and nuances of this relationship. Cross-sectional analyses suggest that 
there are significant linear relationships between waist circumference and blood glucose 
(Branchtein, et al., 1997) and that percent body fat between 26 and 36 weeks, calculated using 
skin fold thicknesses, is higher in women with GDM then in women with normal glucose 
tolerance (Yilmaz, et al., 2010). Although these associations were significant, both of these 
studies lack the ability to give us information regarding the temporality of this relationship. A 
prospective analysis estimated that women with waist circumference measurements in the 
highest tertile before pregnancy were twice as likely to develop GDM as women in the lowest 
tertile (S. Zhang, et al., 1995). Other prospective studies have found that waist circumference 
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measured during pregnancy can predict later development of GDM diagnosis with a sensitivity 
ranging from 63 to 75% and a specificity ranging from 57 to 81% (Madhavan, et al., 2008; 
Wendland, et al., 2007). More compelling results from the Nurses’ Cohort II Study support this 
hypothesis, suggesting that waist circumference has a dose response relationship with GDM 
diagnosis (Yeung, et al., 2010). 
These conclusions are intriguing, but these studies are limited by several factors. For 
example, measuring anthropometric measurements several years before pregnancy and using 
self-reported GDM status (Yeung, et al., 2010; S. Zhang, et al., 1995) may introduce 
misclassification. A low sample size and a racially homogeneous population (Madhavan, et al., 
2008; Yeung, et al., 2010) limit our ability to generalize these results to other populations and 
explore the potential for effect modification by racial status. Finally, collecting anthropometric 
measurements late in pregnancy, i.e. > 26 weeks gestation reduces their accuracy (Wendland, et 
al., 2007). Additionally, only one study assessed the effect of central adiposity on continuous 
glucose tolerance (Branchtein, et al., 1997). 
Excessive GWG and distribution of adiposity may be important predictors of GDM and 
using these measures may give us unique information about how adiposity affects glucose 
intolerance. Previous studies have suggested that there may be a relationship between GDM and 
these measures of adiposity, but there are gaps in our knowledge of these associations. Studies of 
these relationships need to be conducted among a racially diverse population to assess the 
potential interaction of race. Anthropometric measurements must be taken directly before or 
early in pregnancy and new IOM recommendations for GWG should be used. Finally, we 
suggest that future studies in this arena include an assessment of continuous glucose 
measurements as well as risk of GDM diagnosis. As discussed above, this is because women 
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with glucose intolerance below the threshold of GDM diagnosis are also at increased risk for 
poor pregnancy outcomes (Metzger, et al., 2008). 
2.3 OBESITY, MICRONUTRIENTS AND ESSENTIAL FATTY ACIDS 
High adiposity may be an important predictor of GDM on its own, but we are also interested in 
other pathways that may explain how high adiposity affects glucose tolerance. For example, high 
maternal adiposity may be associated with poor micronutrient and EFA status (Figure 4).  
 
 
Figure 4. Proposed relationship between high adiposity (measured by pre-pregnancy BMI) and poor 
nutrition. 
 
Obese women may consume a diet low in key micronutrients and EFAs, but there is also the 
possibility that high adiposity mass alters micronutrient and EFA status by obstructing 
absorption and modifying the metabolism of nutrients. Recent evidence supports the hypothesis 
that high adiposity may be associated with poor micronutrient and EFA status. These 
micronutrients and EFAs are discussed in detail below. For ease of review, our analysis of these 
papers is summarized in Table 1. 
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Table 1. Summary of evidence supporting a relationship between maternal adiposity and nutritional biomarker 
status. 
Nutrient Biology Evidence Quality Prenatal evidence 
Antioxidants Antioxidants may 
prevent the damage 
caused to β-cells by 
oxidative stress. 
Carotenoids: Strong 
Vitamin E: Weak 
Vitamin C: 
Suggestive 
Carotenoids: No 
Vitamin E: No 
Vitamin C: No 
Folate Folate metabolizes 
homocysteine, which 
may inhibit insulin 
secretion. 
Strong No 
EFA n-3 EFAs increase 
insulin sensitivity in 
tissues. 
Suggestive Yes 
Vitamin D β-cells require vitamin 
D to release insulin 
Strong Yes 
*Strong=more than three studies in different populations, at least one having an N≥100, with 
agreement of a significant negative association or correlation (as BMI increases, nutrient 
decreases) and at least one study is a case-control or cohort; Suggestive=one to three studies in 
different populations with agreement of a significant association or correlation; Weak=One third 
or more of the available literature has results that either show a positive correlation (as BMI 
increases, nutrient increases) or has non-significant results.  Evidence will also be classified as 
weak if studies showing a negative correlation are poor quality (very low N, significant potential 
bias, etc.) 
2.3.1 Antioxidants 
Oxidative stress is more common in women with GDM than in healthy pregnant women 
(Chaudhari, Tandon, Vaney, & Agarwal, 2003; Coughlan, Permezel, Georgiou, & Rice, 2004; 
Coughlan, Vervaart, Permezel, Georgiou, & Rice, 2004; Kinalski et al., 2001; Lappas, Permezel, 
& Rice, 2004; Peuchant et al., 2004; Toescu et al., 2004). Pancreatic β-cells are especially 
vulnerable to free radicals and, in times of oxidative stress, can become damaged (Evans, 
Goldfine, Maddux, & Grodsky, 2003). Supplementation with antioxidants may decrease insulin 
resistance in obese patients (Vincent et al., 2009). By raising low-density lipoproteins, increased 
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fat mass may lead to oxidative stress, which in turn may damage pancreatic β-cells and impair 
insulin secretion. Dietary antioxidants, including carotenoids, alpha-tocopherol, and ascorbic 
acid, may prevent oxidative stress during pregnancy and therefore protect against GDM. High 
adiposity may be a moderator in this relationship, but we do not yet understand the relationship 
between high adiposity and antioxidant status. 
Fat mass may contribute to poor antioxidant status in pregnant women by sequestering 
fat-soluble vitamins (carotenoids and vitamin E) or by creating an increased need for 
antioxidants by creating an excess of free radicals. For example, increased plasma low-density 
lipoprotein (LDL) levels lead to an increase in free radicals in normal pregnancy (Toescu, 
Nuttall, Martin, Kendall, & Dunne, 2002; Toescu, et al., 2004). Numerous studies, discussed in 
more detail below, suggest that obese individuals may be at increased risk of antioxidant 
deficiency. 
Carotenoids (e.g. α-carotene, β-carotene, lycopene, lutein/zeanthin, and β-
cryptoxanthin): Decreased serum carotenoid levels have been significantly correlated with 
increased BMI (Ford, Gillespie, Ballew, Sowell, & Mannino, 2002; Galan et al., 2005; 
Kimmons, et al., 2006; Neuhouser et al., 2001) and metabolic syndrome (Coyne, Ibiebele, 
Baade, McClintock, & Shaw, 2009) in a variety of non-pregnant populations. In a more rigorous 
analysis of adiposity, decreased serum β-carotene was significantly associated with general 
adiposity [e.g. bioelectrical impedance analysis (BIA) and BMI] and central adiposity (e.g. waist 
circumference and waist to hip ratios) (Wallstrom et al., 2001). Interestingly, a large prospective 
study reported that adiposity (BMI) at study entry predicted serum carotenoid levels seven years 
later (Andersen, et al., 2006). Similarly, older women with high body fat [as measured by BMI 
and BIA] exhibited smaller increases in plasma carotenoid levels after consuming a high-
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carotenoid diet then lean older women (Yeum, Booth, Roubenoff, & Russell, 1998). These last 
two studies are of special interest because they support the pathway that body fat causes a 
reduction in plasma carotenoid levels. 
Vitamin E: The relationship between vitamin E and fat mass has not, to our knowledge, 
been studied in pregnancy. But, decreasing serum α-tocopherol levels were correlated with 
increasing BMI in two different non-pregnant populations (Kimmons, et al., 2006; Neuhouser, et 
al., 2001). In contrast, Wallström P et al. found that decreasing serum α-tocopherol was 
significantly correlated with decreasing central adiposity among older women (Wallstrom, et al., 
2001).   
Ascorbic acid (vitamin C): In a large cross-sectional analysis of 10,384 healthy women, 
increasing waist-hip ratio was significantly correlated with plasma ascorbic acid (Canoy et al., 
2005). Overweight and obese individuals, have significantly lower levels of serum ascorbic acid 
than normal weight women in some populations (Kimmons, et al., 2006; Tungtrongchitr et al., 
2003) and higher serum ascorbic acid levels in others (Galan, et al., 2005). 
2.3.2 Folate and Homocysteine 
Folic acid plasma concentrations have been associated with endothelial dysfunction in type 2 
diabetics (Mangoni et al., 2005). Additionally, folate is essential for the metabolism of 
homocysteine (Selhub, 2008), an amino acid that inhibits the secretion of insulin in vitro 
(Patterson, Flatt, & McClenaghan, 2007). In non-pregnant populations, there is strong evidence 
that decreased serum folate is associated with increased adiposity, even in a post-folic acid 
fortification era. There is a significant inverse dose response relationship between serum folate 
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and fat mass (BMI and DEXA scans) in post-menopausal women (Mahabir et al., 2008). Obese 
and overweight women have significantly lower levels of serum folate then normal weight 
women in a small Thai population (Tungtrongchitr, et al., 2003) and U.S. women of childbearing 
age (Kimmons, et al., 2006; Mojtabai, 2004). 
2.3.3 Essential fatty acids 
N-3 EFAs, such as linoleic acid, and n-6 EFAs, such as alpha-linolenic acid, have recently 
created a lot of interest because of their potential to increase insulin sensitivity in tissues (Flachs, 
Rossmeisl, Bryhn, & Kopecky, 2009). Increasing visceral fat mass is negatively correlated to 
serum levels of linoleic acid and total EFAs (Kishino et al.). Similarly, increased abdominal 
adipose tissue is associated with decreased serum n-3 EFAs and increased n-6:n-3 ratios in 
adolescent girls (Karlsson, et al., 2006). In healthy pregnant women, increased pregravid BMI 
was significantly associated with decreased plasma DHA (an n-3 EFA) (Wijendran et al., 1999). 
2.3.4 Vitamin D 
Obesity is a well-known risk factor for vitamin D deficiency. In non-pregnant populations, serum 
metabolites of vitamin D have been found to be significantly associated to general and central 
adiposity, measured using body weight, BMI, BIA, DEXA, waist circumference, and skin folds, 
in a variety of populations (Alemzadeh, Kichler, Babar, & Calhoun, 2008; Arunabh, Pollack, 
Yeh, & Aloia, 2003; Bell et al., 1985; S. Cheng et al., 2010; Compston et al., 1981; Hahn et al., 
2006; Hey, Stokholm, Lund, & Sorensen, 1982; Holvik, Meyer, Haug, & Brunvand, 2005; 
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Hypponen & Power, 2006; Kimmons, et al., 2006; Looker, 2005; Nesby-O'Dell et al., 2002; 
Parikh et al., 2004; Snijder et al., 2005; Yanoff et al., 2006; Young et al., 2009). Vitamin D is 
likely to be regulated in the body differently in obese subjects versus lean subjects (Moan, 
Lagunova, Lindberg, & Porojnicu, 2009). In randomized control trials, overweight and obese 
subjects had a significantly reduced response to UV-B irradiation (Wortsman, Matsuoka, Chen, 
Lu, & Holick, 2000) (artificial sunlight) as well as a reduced response to vitamin D 
supplementation when compared to lean subjects (Blum, Dallal, & Dawson-Hughes, 2008; 
Wortsman, et al., 2000). For example, Wortsman et al. exposed 13 obese and 13 lean individuals 
to UV-B irradiation and 11 obese and 11 lean individuals to vitamin D supplements and 
evaluated their serum vitamin D3 before and after. Vitamin D3 levels increased in both groups 
after the treatments, but were significantly lower in the obese groups in both treatments 
(Wortsman, et al., 2000). The relationship between adiposity and vitamin D is further 
complicated by the interaction of race. 25- Hydroxyvitamin D levels are generally lower in black 
women than in white women, but may not be strongly associated with adiposity in black women, 
though an association is seen in white women (Looker, 2005; Winters, Chennubhatla, Wang, & 
Miller, 2009). Obese and overweight pregnant women may be increased risk for vitamin D 
deficiency. Obese pregnant women have been shown to have a higher prevalence (61% versus 
36%; p<0.01) of vitamin D deficiency as measured by 25-hydroxyvitamin D when compared to 
lean pregnant women (Bodnar, Catov, et al., 2007). 
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2.3.5 Summary 
There is strong evidence that obesity is associated with deficiencies of carotenoids, folate, and 
vitamin D. There is suggestive evidence that obese women may be at increased risk for low 
levels of vitamin C and EFA. There is weak evidence that obese women are at increased risk for 
low levels of vitamin E (Table 1). Unfortunately, a large percentage of this literature was 
conducted in non-pregnant populations and, due to the unique nutritional requirements of 
pregnancy (Institute of Medicine (U.S.). Subcommittee on Nutritional Status and Weight Gain 
during Pregnancy. & Institute of Medicine (U.S.). Subcommittee on Dietary Intake and Nutrient 
Supplements during Pregnancy., 1990), cannot be generalized to a pregnant population. 
Overweight and obese pregnant women may have inadequate micronutrient and EFA intake 
through diet and supplements and/or excess fat in overweight and obese women may cause 
alterations in nutrient absorption or metabolism. In an attempt to better understand how poor 
nutrition contributes to glucose intolerance, we will explore vitamin D, the micronutrient with 
the strongest evidence of a relationship to maternal fat mass, in more detail. 
2.4 VITAMIN D AND MATERNAL GLUCOSE CONCENTRATIONS 
Maternal vitamin D deficiency may be a link between obesity and hyperglycemia (Figure 5). The 
most important source of vitamin D is production in the skin through exposure to sunlight 
(Holick, 2004). Vitamin D is also naturally present in fish, shiitake mushrooms, and egg yolk 
and is fortified in many dairy products, breakfast cereals and orange juice (Holick, 2007). 
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Vitamin D obtained from these sources is biologically inert and must first be converted to 25-
hydroxyvitamin D [25(OH)D] in the liver, and then to the physiologically active 1,25-
dihydroxyvitamin D [1,25(OH)2D] in the kidney (van den Berg, 1997). The importance of 
vitamin D to the body is evidenced by the fact that all human tissues that have vitamin D 
receptors (Holick, 2007). Despite the important role vitamin D plays in a woman’s health, poor 
vitamin D status is common among pregnant women. It is estimated that 3% of pregnant women 
in the U.S. are deficient in vitamin D [25(OH)D < 25nmol/L], and 63% have insufficient vitamin 
D status (<75nmol/L) (Looker et al., 2008). Insufficiencies are even more common in black 
pregnant women; it is estimated that up to 92% of black pregnant women have insufficient 
vitamin D status (Looker, et al., 2008). The relatively high prevalence of poor vitamin D status, 
as well as the sizeable disparity in status between black and white pregnant women suggests that 
further investigation of the relationship between adverse birth outcomes, such as maternal 
glucose intolerance, and poor vitamin D status are warranted. 
 
Figure 5. Proposed relationship between poor nutrition (vitamin D) and hyperglycemia 
2.4.1 Biological plausibility 
There are several potential mechanisms for poor maternal vitamin D status to increase maternal 
glucose concentrations. Vitamin D is best known for its role in calcium homeostasis, promoting 
bone mineralization and the prevention of rickets. However, vitamin D has many roles in human 
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health. 1,25(OH)2D is required for the pancreas to release insulin (Kadowaki & Norman, 1985). 
1,25(OH)2D binds to receptors on the pancreatic β-cell and may regulate β-cell calcium 
homeostasis (Norman, Frankel, Heldt, & Grodsky, 1980; Sooy et al., 1999). Also, vitamin D in 
the body ensures an adequate intracellular cytosolic calcium pool, which is essential for glucose 
uptake by insulin-responsive tissues (Draznin et al., 1988). 
Vitamin D deficiency and β-cell dysfunction were strongly associated in healthy, non-
diabetic and diabetic populations (Chiu, Chu, Go, & Saad, 2004; Gedik & Akalin, 1986). Cross-
sectional studies in varying non-pregnant populations have found strong correlations between 
blood glucose levels and 25(OH)D, the primary serum form of vitamin D (Baynes, Boucher, 
Feskens, & Kromhout, 1997; Isaia, Giorgino, & Adami, 2001; Scragg, Sowers, & Bell, 2004). 
Vitamin D supplementation improved blood glucose levels in vitamin D deficient populations 
(Boucher, Mannan, Noonan, Hales, & Evans, 1995). More importantly, a large prospective 
cohort study found that low serum 25(OH)D predicted glycemic status, insulin resistance and 
metabolic disorder in a non-pregnant population (Forouhi, Luan, Cooper, Boucher, & Wareham, 
2008). 
2.4.2 Previous literature 
Recent evidence has explored the possibility that vitamin D is linked to the development of 
GDM. Cross-sectional data suggest that mean serum concentrations of 25(OH)D are significantly 
lower in women with GDM (16.49 nmol/L) than in healthy pregnant women (22.97 nmol/L, 
p<0.05) (Maghbooli et al., 2007) and similar results were found in other cross-sectional analysis 
(Clifton-Bligh, McElduff, & McElduff, 2008). In contrast, Farrant et al reported that maternal 
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hypovitaminosis D (25(OH)D <50 nmol/L) measured at 30 weeks gestation was not associated 
with GDM (Farrant et al., 2009), but they did find that glucose intolerance increased 
significantly as vitamin D concentrations decreased.  These cross-sectional studies provide us 
with a glimpse of the potential relationship between vitamin D and maternal glucose 
concentrations, but they do not provide us with any information regarding temporality. 
The best research to date is a large, nested case-control study (C. Zhang, et al., 2008) that 
found women with vitamin D deficiency at 16 weeks gestation were at 2.66-fold (95% CI: 1.01-
7.02) increased risk for GDM than women with normal vitamin D status. This association was 
significant even after adjustment for maternal age, race/ethnicity, family history of type 2 
diabetes, and pre-pregnancy BMI. This paper was an important contribution to the literature, but 
it was limited by a racially homogenous population and failing to examine continuous glucose 
tolerance, a clinically important outcome measure. 
2.5 SUMMARY OF LITERATURE REVIEW 
Maternal hyperglycemia causes significant maternal and infant morbidity, but is not well 
researched. This has motivated the search for modifiable risk factors for high glucose 
concentrations. Pre-pregnancy BMI is a strong predictor of GDM, but promising literature of 
type 2 diabetes in non-pregnant populations, and limited studies of GDM, have suggested that 
other facets of maternal adiposity may play a more important role in the prediction and 
prevention of maternal hyperglycemia. Exploring patterns of maternal adiposity, such as 
adiposity distribution, central adiposity, and GWG will give us valuable insight into the pathway 
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between maternal adiposity and glucose concentrations. Anthropometric measurements like 
BMI, waist circumference and skin fold thicknesses are accurate, safe methods to describe 
adiposity and adiposity distribution in pregnant women and may predict the risk of maternal 
hyperglycemia. Poor nutrition is likely to play a key role in the relationship between obesity and 
maternal hyperglycemia. There are many studies suggesting that obesity may increase the 
likelihood of poor nutritional status, but there are very few studies that research its role in the 
nutrition of pregnant women, when nutrition is of upmost importance. Further, there are no 
studies known in pregnant women that look at patterns of nutrition across a profile of key 
nutrients. Deficiencies in many nutrients may contribute to the development of maternal 
hyperglycemia. Furthermore, there is compelling biological and epidemiologic evidence to 
suggest that low levels of vitamin D, which is common in pregnant populations, could potentially 
increase the risk of developing high glucose concentrations. These studies, while highly 
suggestive, do not include an analysis of continuous glucose concentrations and a racially diverse 
population. 
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3.0  METHODS 
Using a prospective design, a full panel of maternal micronutrients and EFA biomarkers, a 
population of African American and white pregnant women, and measurement of continuous 
glucose concentrations, our study was better able to describe the contribution of nutrition and 
obesity to maternal hyperglycemia (Figure 6). This is of vital importance because, at a time when 
the rate of GDM is dramatically increasing in the United States (Getahun, et al., 2008), the 
development of effective prevention strategies has the potential to improve the health of many 
women and children. Maternal nutrition and adiposity are modifiable risk factors, and prevention 
strategies, such as nutrition counseling and supplementation, are inexpensive, safe, and 
acceptable to women. Given the profound and long term impact hyperglycemia has on maternal 
and neonatal morbidity, this project has tremendous capacity to benefit public health. 
 
 
Figure 6. Proposed interrelationship between maternal adiposity, poor nutrition, and hyperglycemia 
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3.1 OVERVIEW OF STUDY DESIGN AND STRUCTURE 
We had the unique opportunity to study the interplay between maternal adiposity, micronutrient 
and EFA status, and glucose tolerance using data and specimens from two pregnancy cohort 
studies: the Antidepressant Use during Pregnancy (ADUP) Study and the Study of Nutrition and 
Pregnancy (SNAP). A complete panel of nutritional biomarkers required for Specific Aim 2 was 
not available from the SNAP study within the constraints of our research timeframe, but these 
nutritional biomarkers of interest were collected in total in the ADUP study. Therefore, we 
employed both of these cohorts to achieve the aims of our study. 
3.1.1 The Study of Nutrition and Pregnancy (SNAP) 
SNAP is an ongoing prospective cohort study of the gene-environment interactions that 
contribute to a high-risk phenotype for preterm birth (R01 HD052732, PI: Simhan). In this study, 
women were recruited at Magee-Womens Hospital at <16 weeks gestation and followed through 
labor and delivery to assess birth outcome. Women were approached at their first prenatal visit 
before 16 weeks gestation and asked to participate. At that time, women participated in visit one 
which includes: informed consent, interview, anthropometric measurements and blood draw for 
25(OH)D. Women were asked to return for visit two between 24-28 weeks gestation, which 
includes a second blood draw. For this analysis, we used data from visit one. Women were also 
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routinely screened for GDM using a 50-g 1-hour oral glucose challenge test at 24-28 weeks 
gestation. At delivery, pregnancy outcomes were collected and post-load glucose concentration 
values were obtained from the hospital laboratory electronic database. 
3.1.2 The Antidepressant Use during Pregnancy (ADUP) Study 
The ADUP Study was a prospective cohort study of the effects of antidepressant use and major 
depressive disorder on pregnancy outcomes and child development (R01 MH60335; K Wisner, 
PI). ADUP has completed recruitment and is in the follow-up stage. Pregnant women were 
recruited at < 20 weeks gestation and were followed to 2 years postpartum. Women were asked 
to participate in three visits during pregnancy. The first visit, at approximately 20 weeks, 
included informed consent, interview, and blood draw for nutritional biomarkers. Visits 2 and 3, 
at 30 and 36 weeks gestation, respectively, repeated the blood draw. We used data from the 20 
weeks gestation visit for this analysis. At delivery, pregnancy outcomes were collected. Women 
were also asked to continue participation after delivery, but that data was not included in this 
analysis. 
3.2 DESCRIPTION OF STUDY POPULATIONS 
3.2.1 Description of SNAP Population 
Eligible women were less than 16 weeks gestation, with a singleton pregnancy, and were self 
reported non-Hispanic black or non-Hispanic white. Women were excluded if they have any of 
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the following: pre-gestational diabetes, vaginal bleeding, known thrombophilias, chronic 
hypertension requiring medication, current or planned cervical cerclage, compromised immune 
system (HIV+, use of systemic steroids within 6 months, use of posttransplant 
immunosuppressants), autoimmune disease (e.g. inflammatory bowel disease, systemic lupus 
erythematosus), or known use of illegal drugs or controlled substances. SNAP began recruiting 
women in June of 2003. Data collection for this project ended on May 2010 and blood samples 
were assayed November 2009. As a result, 724 eligible women were included in our analysis of 
adiposity and glucose concentrations and 672 eligible women were included in our analysis of 
vitamin D status and maternal glucose concentrations.  
3.2.2 Description of ADUP Population 
Eligible women had singleton gestations. Women were excluded if they had any of the 
following: psychosis, bipolar disorder, active substance use disorder (identified by self report or 
urine drug screen), gestational exposure to benzodiazepines or prescription drugs in the FDA-
defined category of D or X (other than SSRI) or chronic diseases (such as insulin-dependent 
diabetes). Between 2004 and 2007, ADUP enrolled 197 eligible women who were included in 
our analysis of micronutrient and essential fatty acid status and pre-pregnancy BMI. Women in 
ADUP are primarily older, non-Hispanic white and well educated. 
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3.3 DEFINITIONS AND ASSESSMENT OF MEASURES 
3.3.1 Maternal Adiposity 
Adiposity was measured using pre-pregnancy BMI, biceps and triceps skinfolds thicknesses, 
waist circumferences, and gestational weight gain. 
Pre-pregnancy BMI: Pre-pregnancy weight and height were collected through self-report 
at 20 weeks gestation in ADUP and at <16 weeks gestation in SNAP. BMI was calculated as 
weight (kg) divided by height (m2). A BMI of <18.5 was defined as underweight, 18.5-24.9 as 
normal, 25.0-29.9 as obese, and ≥30 as obese ("Clinical Guidelines on the Identification, 
Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National 
Institutes of Health," 1998). 
Skinfolds: Skinfolds were only measured in SNAP. Biceps skinfold thickness and triceps 
skin fold thickness were collected at <13 weeks gestation. Biceps skinfold thickness was 
measured in the front of the upper arm at the mid-point of the biceps muscle and triceps 
skinfolds thickness was measured at the back of the upper arm on the mid-point of the triceps 
muscles. The skinfolds were measured in mm using calipers by a trained research nurse and 
measurements were taken three times to reduce measurement error. Skinfold thicknesses are 
measures of subcutaneous fat, and therefore can be altered by the changes in water retention 
experienced during pregnancy. As a result, skin folds overestimate subcutaneous fat in 
pregnancy when compared to more rigorous techniques (Sohlstrom & Forsum, 1997; Stevens-
Simon, Thureen, Barrett, & Stamm, 2001). Skinfold thickness measurements also have the 
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potential to be influenced by the fatigue or distraction of the nurse collecting the measurements 
(Norgan, 1992).  
Waist Circumference: Waist circumference was only measured in SNAP. A trained 
research nurse collected waist circumference measurements at <13 weeks gestation. Waist 
circumference is measured at the smallest point of the waist. This measurement was used to 
estimate central adiposity. We also categorized high waist circumference as greater than 88 cm 
("Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and 
Obesity in Adults--The Evidence Report. National Institutes of Health," 1998) and high waist-to-
hip ratio as greater than 0.85 (Madhavan, et al., 2008). Outside of pregnancy, waist 
circumference is well validated (Lapidus et al., 1984; Larsson et al., 1984), but may lose 
accuracy in patients with BMI greater than 35 ("Clinical Guidelines on the Identification, 
Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National 
Institutes of Health," 1998). 
Gestational Weight Gain: Weight gain during pregnancy was measured only in SNAP. 
To maintain temporality, we measured GWG up to the visit where women were screened for 
GDM. Weight in pounds before pregnancy and at each prenatal visit was abstracted from 
medical records, and recalculated into kilograms. Pre-pregnancy weight was self-reported and 
weight at each prenatal visit was measured with clothes on by clinic staff. “Adequate weight 
gain” during pregnancy has been defined using a variety of methods in the previous literature 
(Hedderson, et al., 2010; Herring, et al., 2009; Saldana, et al., 2006; Tovar, et al., 2009). We will 
calculate both the rate of GWG in kg/week and quantify the adequacy of GWG as a ratio of 
observed GWG to expected GWG, similar to the method described by Bodnar et al. (Bodnar, 
Siega-Riz, Simhan, Himes, & Abrams, 2010). 
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Observed GWG was calculated as weight at GDM screening visit minus pre-pregnancy 
weight. Expected GWG will defined as 100% of the 2009 IOM recommendations at the 
gestational age of screening visit (Rasmussen, et al., 2009), which can be found in Table 2. 
 
Table 2. 2009 IOM recommendations for total and rate of maternal weight gain, by pre-pregnancy BMI 
Pre-pregnancy BMI BMI (kg/m2) Total Weight Gain 
Range (kg) 
Mean and (Range) of 
Rates of Weight Gain1 
in 2nd and 3rd 
Trimester (kg/week) 
Underweight < 18.5  12.7 – 18.1 0.45 (0.45-0.59) 
Normal weight 18.5 – 24.9 11.3 – 15.9 0.45 (0.36-0.45) 
Overweight 25.0 – 29.9 6.8 – 11.3 0.27 (0.23-0.32) 
Obese ≥ 30 5.0 – 9.1 0.23 (0.18-0.27) 
IOM, Institute of Medicine; BMI, body mass index 
1Assuming a 0.5–2 kg weight gain in the first trimester (Abrams, Carmichael, & Selvin, 1995; 
Carmichael, Abrams, & Selvin, 1997; Siega-Riz, Adair, & Hobel, 1994) 
 
 
We categorized GWG into inadequate, adequate, and excessive.  There is not a 
recommended range of total GWG up to GDM screening, but we calculated this range using the 
equation for expected GWG and the range of total recommended weight gain in the first 
trimester.  For example, if a woman was obese and was screened for GDM at 24 weeks, then the 
range of recommended total weight gain was: lower limit is 2.5 kg = [0.5 + (24-13) x 0.18] and 
upper limit is 5.0 kg = [2 + (24-13) x 0.27].  We then divided the lower and upper limits of the 
recommended total weight gain range by the expected total weight gain at the gestational age of 
GDM screening for each BMI group and multiply by 100 to calculate ranges of recommended 
percentage of expected weight gain. Using the example above, the expected GWG for an obese 
woman at 24 weeks gestation was 3.0 kg = [0.5 + (24-13) x 0.23]. Therefore, the ranges of 
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percent of recommended GWG were 83% = 2.5/3 to 166%. These ranges of percent of 
recommended GWG were used to categorize GWG adequacy as inadequate if a woman’s 
calculated “% of GWG recommendations met” is less than the lower cutoff of recommendation, 
adequate if it is within recommended range, or excessive if it is greater than the upper cutoff of 
recommendation. 
3.3.2 Nutritional biomarkers 
Micronutrient and EFA status were measured using a panel of maternal nutritional biomarkers. 
The ADUP study previously measured serum carotenoids, serum vitamin E, plasma vitamin C, 
plasma folate, plasma homocysteine, red cell EFAs, serum ferritin, serum soluble transferrin 
receptors, and serum 25(OH)D. Red cell EFA biomarkers were quantified in Dr. Rhobert Evan’s 
Heinz Laboratory and measures of folate and homocysteine were quantified at Dr. Nader Rifai’s 
laboratory at the Boston Children’s hospital. All other biomarkers were quantified by Dr. 
Powers’ laboratory at the Magee-Womens Research Institute. Biomarkers were quantified using 
a variety of methods which are described in detail below and summarized in Table 3.  
 
Table 3. Information on nutritional biomarkers collected in the SNAP and ADUP studies 
Nutrient Biomarker Time integration1 Method of 
measurement 
EFA Red cell membrane EFA Past 2-3 months Gas-liquid 
chromatography 
Folate Plasma folate Past few weeks LC/MS/MS 
Homocysteine Plasma homocysteine Past few weeks LC/MS/MS 
Vitamin A Retinol Past few weeks HPLC 
Vitamin C Plasma ascorbic acid Past few weeks HPLC 
Vitamin D (SNAP) Serum 25-hydroxyvitamin D Past few weeks RIA 
Vitamin D (ADUP) Serum 25-hydroxyvitamin D Past few weeks ELISA/HPLC 
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Vitamin E Serum α-tocopherol Past few weeks HPLC 
Carotenoids2 Serum carotenoids Past few weeks HPLC 
Iron Serum ferritin Past few weeks RIA 
Iron Serum soluble transferrin 
receptors 
Past few weeks ELISA 
EFA = essential fatty acids; LC/MS/MS = liquid chromatography, tandem mass spectrometry; 
HPLC = high-performance liquid chromatography; ELISA = enzyme-linked immunosorbent 
assay; RIA = radioimmunoassay 
1Indicates the time in the past that the biomarker reflects nutritional status (Hunter, 1998). 
2Carotenoids measured will be:  α-carotene, β-carotene, lycopene, lutein/zeanthin, and β-
cryptoxanthin. 
 
Carotenoids, Vitamin E, and Vitamin A Status: Carotenoids, vitamin E and vitamin A all 
fall into the category of lipid soluble antioxidants. Carotenoids are the best known biomarkers of 
fruit and vegetable consumption, and we will measure the most prevalent carotenoids: α-
carotene, β-carotene, lycopene, lutein/zeanthin, and β-cryptoxanthin (Institute of Medicine 
(U.S.). Panel on Dietary Antioxidants and Related Compounds., 2000). There are four 
tocopherols with vitamin E antioxidant activity: α, β, δ, and γ. Although we measured α-
tocopherol, δ-tocopherol, and γ-tocopherol, we only used α-tocopherol to describe vitamin E 
status. Some measures of carotenoid status, such as α-carotene, β-carotene and β-cryptoxanthin, 
also have vitamin A activity. 
The quantization of α-carotene, β-carotene, lycopene, lutein/zeanthin, and β-
cryptoxanthin, α-tocopherol, and retinol, was determined by HPLC using a method based on that 
described by Browne and Armstrong(Armstrong, 1998). Samples were kept in the dark and in 
amber vials.  All samples were analyzed in duplicate and in a blinded fashion. 
We adjusted serum α-tocopherol using two methods. The first method will be by dividing 
α-tocopherol levels by cholesterol, the second by dividing α-tocopherol by total lipids, calculated 
Table 3 continued. 
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as cholesterol plus triglycerides. Serum cholesterol and triglyceride concentrations were 
determined enzymatically using specific reagents from Pointe Scientific (Canton, MI). 
There are not previously defined insufficiency values for carotenoids (Institute of 
Medicine (U.S.). Panel on Dietary Antioxidants and Related Compounds., 2000; Monsen, 2000). 
Thus, we divided carotenoid concentrations into tertiles and define “low carotenoids” as being in 
the lowest tertile of concentration. Previous studies have found that lycopene does not follows 
the same patterns of association as other carotenoids, likely because lycopene response is almost 
entirely due to tomato consumption (Andersen, et al., 2006). We used the Dietary Reference 
Intake (DRI) definitions of insufficient α-tocopherol and retinol concentrations: <16 µmol/L and 
<0.7 µmol/L, respectively (Institute of Medicine (U.S.). Panel on Dietary Antioxidants and 
Related Compounds., 2000; Institute of Medicine (U.S.). Panel on Micronutrients., 2001). There 
are not yet insufficiency levels of either biomarker defined for pregnancy. Insufficiency levels 
have not yet been determined for δ-tocopherol and γ-tocopherol. 
Vitamin C Status: Vitamin C is a water soluble vitamin that has two forms, ascorbic acid 
and dehydroascorbic acid. We used ascorbic acid to measure vitamin C status because it is the 
primary and functional form of vitamin C (Institute of Medicine (U.S.). Panel on Dietary 
Antioxidants and Related Compounds., 2000). 
Maternal plasma ascorbic acid concentrations were determined by HPLC using a method 
based on that described by Rumelin et al. (Rumelin, Fauth, & Halmagyi, 1999). Maternal plasma 
samples were kept cold and in dark vials. Maternal plasma ascorbic acid peaks were separated on 
a Waters (Milford, MA) Atlantis C18. All samples were analyzed in duplicate and in a blinded 
fashion. We assessed two potential insufficiency values for ascorbic acid, <22 µmol/L and <38 
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µmol/L (Institute of Medicine (U.S.). Panel on Dietary Antioxidants and Related Compounds., 
2000; Monsen, 2000). There is no previously value specific to pregnancy. 
Folate Status: Institute of Medicine’s Food and Nutrition Board lists several methods to 
measure folate status (Institute of Medicine (U.S.). Standing Committee on the Scientific 
Evaluation of Dietary Reference Intakes., Institute of Medicine (U.S.). Panel on Folate Other B 
Vitamins and Choline., & Institute of Medicine (U.S.). Subcommittee on Upper Reference 
Levels of Nutrients., 1998). We used two of these measures to quantify folate status: plasma 
folate and plasma homocysteine. Plasma folate is a measure of short-term folate status and, 
therefore, cannot be used to differentiate between chronic folate deficiency and temporary low 
intake(Institute of Medicine (U.S.). Standing Committee on the Scientific Evaluation of Dietary 
Reference Intakes., et al., 1998). But plasma folate is a sensitive measure of dietary folate intake 
and we will strengthen our estimation of folate status by also measuring plasma homocysteine. 
Homocysteine is an amino acid that whose metabolism requires folate. When folate levels are 
low, homocysteine levels rise. 
Plasma folate and plasma homocysteine (Hcy) were quantified in the laboratory of Dr. 
Nader Rifai at the Boston Children’s Hospital. Plasma folate was measured by a quantitative 
sandwich enzyme immunoassay technique on a 2010 Elecsys auto-immunoanalyzer (Roche 
Diagnostics, Indianapolis, IN). Total plasma Hcy was determined by an enzymatic assay on a 
Hitachi 917 analyzer (Roche Diagnostics - Indianapolis, IN), using reagents and calibrators from 
Catch Inc. (Seattle, WA). 
We used a cut-off point of < 16.3 ng/ml to define insufficient folate status, which has 
been previously used as a biologically important insufficiency level in the 2nd trimester of 
pregnancy (Siega-Riz, Savitz, Zeisel, Thorp, & Herring, 2004). We used two sufficiency cut-
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points for homocysteine as well. The value for homocysteine that reflects folate insufficiency in 
non-pregnant populations is >16 µmol/L, but Walker et al. suggests that mean concentration of 
homocysteine in a normal pregnancy are: 5.6 µmol/L at 8-16 wks gestation, 4.3 µmol/L at 20-28 
weeks gestation, and 5.5 µmol/L at 36-42 weeks gestation (Walker, Smith, Perkins, Keely, & 
Garner, 1999). 
Essential Fatty Acid Status: We will explore using n-3 and n-6 polyunsaturated fatty 
acids in our analysis. Lipids were extracted from red blood cells according to the general 
technique of Bligh and Dyer (Bligh & Dyer, 1959). The gas chromatograph was a Perkin Elmer 
Clarus 500. 
There are not well defined insufficiency values for EFAs, although there are for n-6:n-3 
ratios (Institute of Medicine (U.S.). Panel on Macronutrients. & Institute of Medicine (U.S.). 
Standing Committee on the Scientific Evaluation of Dietary Reference Intakes., 2005). We will 
divide n-3 and n-6 polyunsaturated fatty acids into tertiles and define “low EFA” as being in the 
lowest tertile of concentration.  
Iron Status: We used two measures of iron status: serum ferritin and soluble transferrin 
receptor (sTfR) concentration. Serum ferritin reflects the body’s iron stores, and low values can 
be a sign of early iron deficiency. A high concentration of sTfR is also indicators of low 
functional iron status but, unlike ferritin concentration, is less sensitive to infections and 
inflammatory conditions (Institute of Medicine (U.S.). Panel on Micronutrients., 2001). 
Serum ferritin levels were analyzed using an immunoradiometric assay with I-125 
labeled anti-ferritin antibody in a kit obtained from DPC (catalog # IKFE1, Los Angeles, CA). 
Serum sTfR levels were measured using an enzyme-linked immunosorbent assay (ELISA) from 
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by R&D Systems (Minneapolis MN). All samples were analyzed in duplicate and in a blinded 
fashion. 
The DRI defines insufficiency values for ferritin as <12 µg/L or <20 µg/L (Institute of 
Medicine (U.S.). Panel on Micronutrients., 2001), based on a non-pregnant population. Previous 
studies of sTfR concentrations in pregnancy have used a cut-off of >8.5 mg/L to indicate iron 
deficiency (Akesson, Bjellerup, Berglund, Bremme, & Vahter, 1998, 2002). 
Vitamin D Status: Serum concentration of 25(OH)D is the best indicator of vitamin D 
status. It reflects vitamin D produced in the skin and obtained from food and supplements and 
has a long circulating half-life. Serum 25(OH)D levels do not indicate the amount of vitamin D 
stored in other body tissues. 
There are many assays to measure 25 (OH) D concentrations currently in use, including 
competitive protein binding with vitamin D binding protein, radioimmunoassay (RIA), and 
enzyme-linked immunosorbent assay (ELISA). There is high inter- and intra- variability in the 
assays used to measure vitamin D status and no established standard method to assay 25-
hydroxyvitmain D concentrations(Binkley et al., 2004), although HPLC is currently considered 
to be the gold standard (Holick, 2009). 
In SNAP, concentrations of serum 25-hydroxyvitamin D were quantified using a 
DiaSorin radioimmunoassay (RIA). The RIA detects 100% of 25-hydroxy-ergocalciferol and 
100% of 25- hydroxyl-cholecalciferol. Maternal serum samples were stored in aliquots at –80°C 
until they were analyzed for 25-hydroxyvitamin D [25-hydroxy-erocalciferol + 25-hydroxy-
cholecalciferol]. The interassay CV was 9.5%. The detectable limits for the RIA are 3.75 to 250 
nmol/L and none of the samples of 25-hydroxyvitamin D included in our analysis fell outside 
this range.  
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Concentrations of serum 25-hydroxyvitamin D in ADUP were measured using a 
commercial ELISA from Immunodiagnostic Systems Limited (IDS, Tyne, United Kingdom) in 
ADUP. The ELISA assay can detect serum concentrations of 25-hydroxyvitamin D between 5-
300 nmol/L. ELISA results were validated against a HPLC method carried out in Dr. Powers’ 
laboratory at the Magee-Womens Research Institute as described previously (Bodnar et al., 
2007). All samples are analyzed in duplicate and in a blinded fashion. 
The appropriate cut-off for vitamin D insufficiency in non-pregnant populations is 
currently under debate and potential cut-offs range from <37.5 nmol/L (Institute of Medicine 
(U.S.). Standing Committee on the Scientific Evaluation of Dietary Reference Intakes., 1997) to 
<80 nmol/L(Hollis, 2005). There is not yet an established insufficiency value for pregnant 
women, so we explored multiple cut-offs in our analysis. 
3.3.3 Post-load glucose concentration 
All maternal glucose concentration values were obtained from electronic laboratory records and 
were only collected in SNAP. At Magee-Womens Hospital, where SNAP is conducted, post-load 
glucose concentrations were obtained using a 50-g, 1-hour oral glucose challenge test at 
approximately 24-28 weeks gestation. If the post-load glucose concentration was > 135 to 140 
mg/dl, then women are also given a 100-g, 3-hour glucose challenge test  Women were 
diagnosed with GDM if their 50-g 1-hour post-load glucose concentration was ≥ 180 mg/dl, or if 
two or more of their 100-g 3-hour oral glucose tolerance results were abnormal (Carpenter & 
Coustan, 1982). We analyzed post-load glucose concentrations because recent evidence has 
found that, in women below the threshold of GDM, the risk of adverse prenatal outcomes 
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increases significantly with increasing blood glucose levels (Metzger, et al., 2008). We did not 
have an adequate number of women diagnosed with GDM to assess GDM as an outcome 
variable.  
3.3.4 Covariates 
The following confounders were assessed for our analyses in both ADUP and SNAP: maternal 
age, race/ethnicity, parity, employment, education, marital status, and smoking status during 
pregnancy. Analyses in SNAP were additionally adjusted for gestational age of GDM screening, 
family history of gestational diabetes, income, and season of 25(OH)D measurement. Analysis in 
ADUP was additionally be adjusted for depression status. Maternal age, race/ethnicity, parity, 
income, employment, education, marital status, and smoking status were obtained by self-report 
at the first visit in both SNAP and ADUP. These socioeconomic and social factors were 
important to include in our analysis because these have been shown to be significant risk factors 
for obesity, nutrition, and gestational diabetes (Anna, van der Ploeg, Cheung, Huxley, & 
Bauman, 2008; James, Nelson, Ralph, & Leather, 1997). Depression status in ADUP was 
determined by trained research clinical staff. Family history of diabetes was abstracted from 
medical records after delivery in SNAP only. For the evaluation of the association between 
vitamin D status and maternal glucose concentration (specific aim 3), we also controlled for 
season of serum 25(OH)D sample to account for the amount of available sunlight and its affect 
on serum 25(OH)D status. 
There are some potential covariates that will not be measured in our study. For example, 
measures of physical activity, type of adiposity (e.g. fat mass versus fat-free mass), genetic 
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factors, inflammation, and water retention were not collected in either study and income was not 
measured in ADUP and these unmeasured confounders may influence our analyses. 
Additionally, data on dietary intake, supplements and sunlight exposure were not included in our 
analyses. Women who are considered to be at “high risk” for gestational diabetes may be 
referred to nutritional counseling, and the affect of this intervention is also not measured in our 
study. Although all women in SNAP were screened for GDM during pregnancy we did not 
measure glucose levels before pregnancy. Therefore, we are not able to differentiate between 
women who had undiagnosed type 2 diabetes before pregnancy and women for whom glucose 
intolerance began during pregnancy. For some of these unmeasured covariates, we have 
measured variables that can be used as proxy measurements. For example, while we do not have 
income measurements in ADUP, we do have other related measures of socioeconomic status. 
Other covariates, such as physical activity, are strongly related to adiposity, nutrition, and 
glucose tolerance, and will have more of an effect on our analysis. 
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4.0  THE ROLE OF GESTATIONAL WEIGHT GAIN AND EARLY PREGNANCY 
MATERNAL ADIPOSITY DISTRIBUTION AND THE DEVELOPMENT OF 
MATERNAL HYPERGLYCEMIA 
4.1 ABSTRACT 
Gestational weight gain (GWG) and maternal adiposity distribution may be important risk 
factors for maternal hyperglycemia. The objective of our study was to estimate the effects of 
GWG, central adiposity and subcutaneous fat on maternal post-load glucose concentration. 
Pregnant women (n = 413, 62% black, 57% with BMI≥25) enrolled in a cohort study at <16 
weeks gestation. GWG was abstracted from medical records. In a sub-sample of women (n = 
214), waist circumference, subcutaneous fat biceps and triceps skinfold thicknesses were 
measured at enrollment. At 24-28 weeks gestation, post-load glucose concentration was 
measured using a 50-g 1-hour oral glucose tolerance test. After adjustment for confounders, 
including pre-pregnancy BMI, each 0.3-kg/week increase in weight at ≤ 13 weeks gestation was 
associated with a 2.2 (95% CI: 0.1, 4.3)-mg/dl increase in glucose concentration. After 
adjustment for confounders, each 8.6-mm increase in biceps skinfold thickness and 11.7-mm 
increase in triceps skinfold thickness was associated with a 4.3 (95% CI: 0.2, 8.5)-mg/dl 
increases in maternal glucose. Neither GWG in the second trimester nor waist circumference at ≤ 
13 weeks was significantly associated with glucose concentration after confounder adjustment. 
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Independent of pre-pregnancy BMI, high early pregnancy GWG and maternal subcutaneous 
body fat may elevate the risk of gestational hyperglycemia, which in turn, increases the risk of 
adverse birth outcomes. 
4.2 INTRODUCTION 
Gestational diabetes mellitus (GDM), defined as glucose intolerance with onset or first 
recognition during pregnancy, occurs in 4% of pregnancies (Getahun, et al., 2008) and is a major 
risk factor for a variety of adverse maternal and child outcomes including birth trauma, 
macrosomia, and later development of type 2 diabetes mellitus (Henriksen, 2008; Jevitt, 2005; C. 
Kim, et al., 2002). Importantly, maternal hyperglycemia, defined as high blood sugar during 
pregnancy, below the threshold of GDM is associated with similar poor birth outcomes 
(Metzger, et al., 2008). Clearly, a better understanding of the risk factors of high glucose in the 
prenatal period is imperative to improving the health of women and their infants.  
Obesity, often measured by pre-pregnancy body mass index (BMI), is strongly associated 
with GDM in a variety of populations (Chu, et al., 2007; Haeri, et al., 2009; Hedderson, et al., 
2008; Joy, et al., 2009; Knight, et al., 2010; Leung, et al., 2008; Nohr, et al., 2009; Qvigstad, et 
al., 2010; Shirazian, et al., 2009; Torloni, et al., 2009; van Leeuwen, et al., 2010). However, BMI 
has limitations as a measure of adiposity (Romero-Corral, et al., 2008) and cannot be measured 
during pregnancy because of the increase in weight not related to adiposity. Additionally, pre-
pregnancy BMI only measures general adiposity, and women with similar BMI values may have 
widely varying distribution of their adipose tissue (Romero-Corral, et al., 2008). 
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Excessive adiposity during pregnancy, as measured by gestational weight gain (GWG) 
and maternal fat distribution, may be important risk factors of GDM. Despite our increasing 
knowledge of the physiological effect of excess fat accumulation on insulin resistance during 
pregnancy (Harlev & Wiznitzer, 2010), few studies have quantified the effects of GWG and fat 
distribution on the risk of GDM. A recent case-control study suggested that excessive weight 
gain, especially in the first trimester, is associated with GDM (Hedderson, et al., 2010), and 
studies of maternal fat distribution have suggested that central adiposity and subcutaneous 
adipose tissue may be associated with maternal post-load glucose concentration and GDM 
(Branchtein, et al., 1997; Wendland, et al., 2007; Yeung, et al., 2010; Yilmaz, et al., 2010). 
These studies were limited by the use of anthropometric measures taken years before pregnancy 
and self-reported GDM (Yeung, et al., 2010; S. Zhang, et al., 1995), low sample sizes and a 
racially homogeneous populations (Madhavan, et al., 2008; Yeung, et al., 2010), and 
anthropometrics measured late in pregnancy, which reduces the accuracy of measurement 
(Wendland, et al., 2007).  
The objective of our study was to determine the association between GWG up to the time 
of GDM screening, first trimester central adiposity and subcutaneous fat on maternal post-load 
glucose concentration. 
4.3 METHODS 
We analyzed data from the Study of Nutrition and Pregnancy (SNAP), a prospective pregnancy 
cohort study of women receiving care in the prenatal clinics at Magee-Womens Hospital of 
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UPMC in Pittsburgh, PA. Women seeking care at the clinics are primarily low-income, 
publically insured, and approximately 50% African American. Eligible women had singleton 
pregnancies and were self-reported non-Hispanic black or non-Hispanic white. Participants were 
excluded if they had pre-gestational diabetes, vaginal bleeding, thrombophilias, chronic 
hypertension requiring medication, current or planned cervical cerclage, compromised immune 
system, autoimmune diseases, or known use of illegal drugs or controlled substances. At 
enrollment participants provided informed, written consent. The study was approved by the 
University of Pittsburgh Institutional Review Board. 
Between June 2003 and May 2010, 724 eligible pregnant women were enrolled at < 16 
weeks’ gestation [mean (SD) gestational age = 9.1 (2.9) weeks]. At enrollment, women 
completed a structured interview that included questions on socio-demographic factors and 
medical history. Of those eligible, we excluded women who had a spontaneous or therapeutic 
abortion (n = 85), implausible weight measurements (n = 2), or a first prenatal visit after the first 
trimester (n = 53). Women were also excluded if the prenatal visit closest to their GDM 
screening visit was > 30 days before the screening (n = 8) or because of GDM screening < 24 
weeks gestation (n = 43). A total of 82 women were excluded because measured weight at the 
last visit before GDM screening was missing from their medical record and GWG could not be 
calculated. Of these 82 women, 22 women transferred care to another facility. There were no 
missing glucose concentration values. An additional 38 women were excluded because they were 
missing data on one of the covariates included in the final model. A total of 413 women were 
included in the final analysis. Women excluded from our analysis were more likely to be 
smokers (56% versus 44%, p < 0.05) and nulliparous (39% versus 21%, p < 0.01) than women 
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included in the analysis. There were no other meaningful differences in post-load glucose 
concentrations and other maternal characteristics (data not shown). 
In June 2006, waist circumference and skinfolds measurements were added to the study 
protocol at ≤ 13 weeks gestation [mean (SD) = 8.5 (2.0) weeks gestation] and, therefore, these 
measurements were available only in a sub-sample of women (n = 436). After the exclusions 
made above, a total of 214 were available for analysis of adiposity distribution.  
A 50-g 1-hour oral glucose challenge test was performed as part of routine clinical care at 
approximately 24-28 weeks gestation to screen for GDM. The post-load glucose concentration 
values were abstracted from medical records. Women with post-load glucose concentration 
values >135 mg/dL additionally received a 3-hour 100-g oral glucose tolerance test. Women with 
50-g 1-hour post-load glucose concentration values ≥ 180 mg/dL, or 2 or more abnormal 3-hour 
100-gram oral glucose tolerance results were classified as having GDM (Carpenter & Coustan, 
1982). Additionally, in our sample, a total of 45 women considered by their clinician to be at 
high risk for GDM underwent early screening [< 24 weeks gestation, mean (SD), 17.2 (6.9)]. To 
ensure that our results were comparable to other studies, women with early GDM screening were 
excluded from our analysis.  
We calculated the first trimester rate of GWG as the difference between weight measured 
at the last prenatal visit in the first trimester (≥ 8 weeks gestation and < 14 weeks gestation, “first 
trimester visit”) and the pre-pregnancy weight divided by the weeks of gestation at the first 
trimester visit. The second trimester rate of GWG was defined as the difference between the 
weight at GDM screening test and the weight at the first trimester visit divided by the number of 
weeks between measurements. The total average rate of GWG up to GDM screening was 
calculated as the difference between the measured weight at or before GDM screening and the 
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self-reported pre-pregnancy weight, divided by the weeks of gestation at the time of the weight 
measurement. The difference between the measured weight and GDM screening was, on 
average, less than 1 week [mean (SD) = 0.5 (1.6) weeks]. We defined adequacy of weight gain 
up to GDM screening using the 2009 IOM recommendations (Rasmussen, et al., 2009). The ratio 
of the observed to expected GWG was classified as inadequate, adequate, or excessive, as 
described previously (Bodnar, Siega-Riz, Simhan, Himes, et al., 2010). 
For the women whose self-reported pre-pregnancy weight was deemed biologically 
improbable (n = 45, ≥ 6.8 kg gained or lost between pre-pregnancy weight and first prenatal visit 
≤ 13 weeks gestation), we imputed pre-pregnancy weight based on a back calculation using the 
rate of weight gain between the first two prenatal visits, similarly to previously used methods 
(Laraia, Siega-Riz, & Gundersen, 2010). If the second weight measurement was after 16 weeks’ 
gestation, we did not impute a pre-pregnancy weight (n = 5). 
Central adiposity was assessed using waist circumference measured at < 13 weeks 
gestation. Waist circumference was measured at the smallest point of the waist by a trained 
research nurse. “At risk” waist circumference was defined as greater than 88 cm ("Clinical 
Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in 
Adults--The Evidence Report. National Institutes of Health," 1998). Because waist 
circumference measurements lose accuracy in patients with BMI ≥ 35 ("Clinical Guidelines on 
the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The 
Evidence Report. National Institutes of Health," 1998), we performed a sensitivity analysis by 
excluding women with a BMI ≥ 35. Subcutaneous fat was described using biceps and triceps 
skinfolds, measured by a trained research nurse at < 13 weeks. Biceps skinfold thickness was 
measured in the front of the upper arm at the mid-point of the biceps muscle using calipers. The 
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triceps skinfolds were measured at the back of the upper arm on the mid-point of the triceps 
muscle ("National Heart, Lung, and Blood Institute: Obesity Education Initiative: "The Practical 
Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults.","). To 
reduce measurement error, biceps and triceps skinfolds measures were taken three times and the 
mean was used for analysis. If women had an outlying value, defined as a difference between the 
lowest and highest of the triplicate that was greater than two standard deviations from the mean 
of all three measurements, we calculated the mean of the two remaining values (triceps: n = 10; 
biceps: n = 14).   
Maternal demographics and pre-pregnancy weight were obtained by self-report at 
enrollment. Family history of diabetes was abstracted from medical records after delivery. Pre-
pregnancy BMI was calculated as pre-pregnancy weight (kg) divided by height (m) squared. A 
BMI of <18.5 was defined as underweight, 18.5-24.9 as normal weight, 25.0-29.9 as overweight, 
and ≥ 30 as obese ("Clinical Guidelines on the Identification, Evaluation, and Treatment of 
Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health," 1998). 
Maternal post-load glucose concentration was used as a continuous outcome variable 
because elevated post-load glucose concentrations, even below the threshold of GDM diagnosis, 
have been shown to be strongly associated with adverse pregnancy outcomes (Metzger, et al., 
2008). Separate multivariable linear regression models were used to assess the association 
between each independent variable (average rate of GWG, GWG adequacy, waist circumference, 
and skinfolds) and post-load glucose concentration. The relationship of each independent 
variable with post-load glucose was assessed by visual inspection of lowess smoothing plots. 
Because no meaningful deviations from linearity were observed, independent variables were 
specified as continuous. GWG adequacy was categorized to ensure greater interpretability. 
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Potential confounders were maternal age, parity, race/ethnicity, smoking status, marital status, 
annual family income, education, family history of diabetes and gestational age of glucose 
challenge test.  Pre-pregnancy BMI was included in all models out of convention. We defined 
confounding as a > 10% change in the adjusted beta coefficient after exclusion of the covariate 
from the full model. To maintain comparability across models, the full model was used for all 
four of the final GWG models. Because of the smaller sample size, we assessed confounding in 
the adiposity distribution measurements separately from the GWG models. Pre-pregnancy BMI, 
maternal age, parity, race/ethnicity, maternal education, and family history of diabetes were all 
found to be confounders in the skinfolds and waist circumference models.  
Pre-pregnancy BMI and race/ethnicity were evaluated as effect modifiers in each model 
by including the interaction term in the model and testing for significance using the Wald test (α 
< 0.05). To explore the interaction between first- and second-trimester rates of GWG on post-
load glucose concentrations, we stratified women based on whether they were above or below 
the mean rates of weight gain in each trimester. We used Student’s t-test to compare the 
differences in mean post-load glucose concentrations between these four groups, using women 
with GWG rate below the mean in both the first and second trimesters as the reference. Our 
sample size was not large enough to test this interaction using regression analysis. Data were 
analyzed using STATA software version 11.0 (StataCorp, College Station, TX). 
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4.4 RESULTS 
Women in our cohort tended to be young, multiparous, African American, unmarried, high 
school educated or less, and had no family history of diabetes (Table 4). Approximately half the 
women were smokers, low income, and unemployed and more than a third were obese. 
The mean (SD) post-load glucose concentration was 99.7 (24.3) mg/dl and ranged from 
43 to 200 mg/dl. GDM screening occurred at a mean (SD) of 27.3 (2.3) weeks gestation. A total 
of 45 (9.0%) of women had post-load glucose concentrations ≥ 135 mg/dl, and of these women, 
eleven women (2.7% of total cohort) were diagnosed with GDM. 
The mean (SD) weeks gestation for the first trimester visit was 11.7 (1.3) weeks, with a 
range of 8.2-13.6 weeks. On average, women gained approximately 1.4 (SD: 4.1) kg in the first 
trimester and 6.0 (SD: 4.4) kg in the second trimester. More than half of women had excessive 
weight gain before GDM screening (Table 5). In the unadjusted analysis, first trimester average 
rate of GWG and total average rate of GWG were linearly associated with post-load glucose. 
After adjustment for age, parity, race/ethnicity, smoking status, marital status, income, education, 
family history of diabetes, gestational age at GDM screening and pre-pregnancy BMI, each 0.3 
kg/week of GWG (4 kg total) in the first trimester was associated with nearly a 2 mg/dL increase 
in maternal blood glucose. In both the unadjusted and adjusted models, total average rate of 
weight gain, second trimester specific rate of gain, and GWG adequacy were not significantly 
associated with maternal glucose. Pre-pregnancy BMI and race/ethnicity did not modify any of 
these associations.  
We also examined the interaction between first and second trimester average rate of 
GWG in unadjusted analysis. Overall, the inclusion of this interaction did not significantly 
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modify the relationship between GWG rate and maternal post-load glucose concentration (p = 
0.07). Women whose first trimester rate of GWG was ≥ 0.12 kg/week, regardless of the second 
trimester rate of gain, tended to have higher mean post-load glucose concentrations than women 
whose rate of GWG was below the mean in both trimesters (Table 6). This difference, however, 
did not reach statistical significance.  
In unadjusted analyses biceps and triceps skinfolds had positive, linear associations with 
post-load glucose concentration (Table 7). After adjustment for pre-pregnancy BMI, maternal 
age, parity, race/ethnicity, maternal education, and family history of diabetes, each standard 
deviation increase in biceps and triceps skinfold thicknesses was associated with an 
approximately 4.3 mg/dl increase in maternal glucose. Each standard deviation increase in waist 
circumference was associated with an approximately 4.5 mg/dl increase in maternal glucose 
concentration in unadjusted analysis. However, after adjustment, the relationship was no longer 
statistically significant. Pre-pregnancy BMI and race/ethnicity did not modify any of these 
associations. No meaningful differences were detected when we excluded women with a BMI ≥ 
35 from the analysis or when we excluded women whose waist circumference measurements 
were obtained > 10 weeks gestation. 
4.5 DISCUSSION 
We found that a high rate of GWG in the first trimester and elevated biceps and triceps skinfold 
thicknesses were positively associated with high post-load glucose concentrations at the GDM 
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screening. These associations were independent of important confounders, such as pre-pregnancy 
BMI, socioeconomic factors and medical history.  
The 2009 Institute of Medicine Committee to Revise Gestational Weight Gain Guidelines 
highlighted that more evidence was needed to determine the role that GWG plays in the 
development of GDM (Rasmussen, et al., 2009), but few studies have been published to examine 
this association. And, given the increased risk to pregnant women for adverse outcomes 
(Metzger, et al., 2008), a rigorous examination of the relationship between adiposity and 
maternal hyperglycemia, and not just GDM, is warranted. Interventions to decrease maternal 
glucose concentrations by controlling maternal GWG through programs of exercise, dietary, 
pharmaceutical or a combination of the three had inconsistent results (Callaway et al., 2010; 
Oostdam, et al., 2011). However, there are effective interventions that suggest that not only is 
GWG a modifiable risk factor, but that controlling GWG can reduce incidence of GDM 
(Quinlivan, et al., 2011).  
Our conclusion that first trimester rate of GWG is independently associated with maternal 
hyperglycemia is in agreement with a recent nested case-control study that found that women 
who gained in the highest tertile of first trimester weight gain rate were more likely to develop 
GDM then women who gained in the lowest tertile of weight (Hedderson, et al., 2010).  A 
second study examined the relationship between weight gain and impaired glucose tolerance 
(IGT) as well as GDM, stratified by early and mid-pregnancy (Herring, et al., 2009). 
Interestingly, the authors found that women who had high weight gain in both early and mid-
pregnancy were more likely to develop IGT, but not GDM, compared with women who had low 
weight gain in both periods. These researchers found a significant interaction between early and 
mid-pregnancy, whereas we did not have the power to include this interaction. 
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Our conclusions are in agreement with several previously published studies that have 
found no association between total weight gain up to GDM screening and GDM (Herring, et al., 
2009; Tovar, et al., 2009), and adequacy of gain and GDM (Saldana, et al., 2006; Tovar, et al., 
2009). Although, Tovar et al. found that among women with a pre-pregnancy BMI ≥ 35 kg/m2, 
women who exceeded their target weight (expected weight gain based on IOM criteria) were 
approximately four times as likely to have abnormal glucose tolerance than women who met 
their target weight (Tovar, et al., 2009). It is important to note, however, that the researchers 
studied abnormal glucose tolerance rather than post-load glucose concentrations or overt GDM. 
More compellingly, Hedderson et al. found that women who exceeded the 2009 IOM weight 
gain recommendations were approximately 1.5 times as likely to have GDM than women who 
were below or within the recommendations (Hedderson, et al., 2010). The differences in our two 
studies may be explained by the small effect size that Hedderson et al. found, and our sample 
may not have been large enough to assess this effect.  
Increases in weight and insulin resistance are normal physiological changes of pregnancy. 
But excess fat accumulation can cause high concentrations of free fatty acids, altered adipokine 
expression, and low-grade inflammation, all of which are thought to increase insulin resistance 
(Ioannidis, 2008). Consequently, this may contribute to the development of abnormally high 
levels of glucose concentrations during pregnancy. The differences in early pregnancy weight 
gain and total weight gain results may arise because early weight gain is largely fat accumulation 
and total weight gain is not (van Raaij, Peek, Vermaat-Miedema, Schonk, & Hautvast, 1988). 
The effect of maternal adiposity distribution on risk of maternal hyperglycemia has not 
been extensively researched. Our result that biceps and triceps skinfolds in the first trimester are 
independently associated with maternal hyperglycemia is supported by a cross-sectional analysis 
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of Turkish women (n = 98) that suggested that percent body fat at 26 to 36 weeks gestation, 
calculated using skinfold thicknesses, was significantly higher in women with GDM then in 
women with normal glucose tolerance (Yilmaz, et al., 2010). While we found no relationship 
between waist circumference at < 13 weeks and glucose concentrations, others have noted 
positive associations between pre-pregnancy waist circumference and waist circumference at the 
time of GDM screening and hyperglycemia and GDM status (Branchtein, et al., 1997; 
Wendland, et al., 2007; Yeung, et al., 2010). The difference in our results may arise from several 
factors. We measured early pregnancy waist circumference, whereas other studies used self-
reported pre-pregnancy waist circumference (Yeung, et al., 2010) or measured waist 
circumference at mid-pregnancy (Branchtein, et al., 1997; Wendland, et al., 2007). Waist 
circumference measured in mid-pregnancy loses accurate measure of adiposity (McCarthy, et al., 
2004). Also, our study had a larger percentage of African American pregnant women than other 
studies. Some evidence in non-pregnant populations that suggests that relationship between waist 
circumference and insulin resistance may be different in African Americans than in whites 
(Sumner et al., 2008), although we did not find that race/ethnicity modified these associations in 
our population.  
High subcutaneous fat has been associated with decreased insulin resistance in non-
pregnant populations (Goodpaster, Thaete, Simoneau, & Kelley, 1997), and there is some 
evidence that diabetes and obesity during pregnancy may cause defects in the insulin-signaling 
pathway in subcutaneous adipose tissue in pregnant women (Colomiere, Permezel, & Lappas, 
2010). Importantly, studies in non-pregnant cohorts that suggest that abdominal visceral fat 
thickness has a stronger association than subcutaneous fat (Bartha et al., 2007; Liu et al., 2010). 
Unfortunately, our methods could not differentiate abdominal visceral fat from subcutaneous fat. 
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More studies are needed to understand the role that adiposity distribution plays in the etiology of 
maternal hyperglycemia. 
Strengths of our study include an assessment of continuous maternal post-load glucose 
concentrations. Glucose concentrations below the threshold of overt GDM have been previously 
associated with poor birth outcomes (Y. W. Cheng, McLaughlin, Esakoff, Block-Kurbisch, & 
Caughey, 2007) and were strongly associated to large-for-gestational age infants in our cohort 
(data not shown). Furthermore, our cohort was composed of African American and white women 
and we included an analysis of the effects of trimester-specific GWG and maternal fat 
distribution in early pregnancy on maternal post-load glucose. However, our cohort was 
composed of generally young, non-Hispanic women with singleton pregnancies and no previous 
history of GDM. Therefore, only a small percentage of women in our cohort developed GDM, 
and our study did not have the power needed to explore a rigorous analysis of GDM status. Our 
analysis of continuous glucose allowed us to examine the linearity of the relationship between 
adiposity and maternal post-load glucose, even in women who were not diagnosed with GDM, 
and high glucose in women without GDM is associated with adverse pregnancy outcomes 
(Metzger, et al., 2008). Our sample size was small, limiting the precision of our results and our 
ability to examine the interaction between trimester and GWG. Skinfold thicknesses are 
measures of subcutaneous fat, and therefore can be altered by the changes in hydration 
experienced during pregnancy. All anthropometric techniques have the potential to be influenced 
by human error (Norgan, 1992), but this limitation was mitigated in our study with the use of a 
trained research nurse taking three individual measurements.  
Our results may be biased by unmeasured confounding from physical activity, genetic 
factors, and type of GWG (e.g. fat mass versus fat-free mass). Physical activity is associated with 
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reductions in weight gain (Lee, Djousse, Sesso, Wang, & Buring, 2010) and decreased insulin 
resistance (Church, 2011), and this would bias our results away from the null. Certain genetic 
factors may increase the risk of development of hyperglycemia (Freathy et al., 2010), and these if 
these factors also have an effect on GWG or adiposity distribution our results may be biased in 
either direction, depending on the effect. Although type of GWG has not been well studied, 
research in non-pregnant populations has suggested that gains in visceral adipose tissue and 
intermuscular adipose are associated with type 2 diabetes (Gallagher et al., 2009). If this 
association is also true in pregnancy, than the effect of GWG that we observed actually may be 
due, in part, to a type of adipose tissue. Because we did not measure glucose levels before 
pregnancy, we were not able to differentiate between women who had undiagnosed type 2 
diabetes before pregnancy from women for whom glucose intolerance began during pregnancy, 
which limits inferences about the temporality of the associations. Future studies of continuous 
maternal glucose with larger sample sizes, more rigorous measures of adiposity, and analyses of 
trimester-specific GWG are warranted.  
If confirmed by more extensive study, our results that first trimester GWG and early 
subcutaneous fat may play important roles in the development of hyperglycemia will provide 
valuable insight into the etiology of maternal hyperglycemia and the role that adiposity may play 
in its development. Excessive adiposity during pregnancy is a modifiable risk factor and a better 
understanding of its relationship with glucose concentrations made lead to more effective 
targeted interventions to reduce the risk of maternal hyperglycemia and improve maternal and 
fetal outcomes. 
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4.6 FIGURES AND TABLES 
Table 4. Maternal characteristics of SNAP participants, n = 413 
Characteristic  
Age at enrollment, mean (SD) 24.4 (4.5) 
Parity, N (%)  
     0 88 (21.3) 
     1-7 325 (78.7) 
Race/ethnicity, N (%)  
     White 159 (38.5) 
     African American 254 (61.5) 
Smoking status, N (%)  
     Smoker 180 (43.6) 
     Non-smoker 233 (56.4) 
Marital status, N (%)  
     Married 61 (14.8) 
     Not married 352 (85.2) 
Annual family income, N (%)  
     < $10,000 177 (42.9) 
     ≥ $10,000 236 (57.1) 
Educational status, N (%)  
     Greater than a high school degree 49 (11.9) 
     High school educated 364 (88.1) 
Family history of diabetes, N (%)  
     History of diabetes 152 (36.8) 
     No history of diabetes 261 (63.2) 
Employment status, N (%)  
     Employed 224 (54.2) 
     Not employed 189 (45.8) 
Pre-pregnancy BMI (kg/m2), mean (SD) 28.0 (7.4) 
     Underweight (<18.5), N (%) 13 (3.1) 
     Normal weight (18.5-24.9), N (%) 165 (40.0) 
     Overweight (25-29.9), N (%) 91 (22.0) 
     Obese (30+), N (%) 144 (34.9) 
BMI = body mass index 
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Table 5. Unadjusted and adjusted association between maternal blood glucose < 24 weeks gestation and maternal 
GWG, n = 413 
 mean (SD) 
kg/week 
Unadjusted β 
(95% CI) 
Adjusted1  
β (95% CI) 
1st trimester average rate of GWG, 
     per 0.3 kg/week increase 0.1 (0.3) 2.5 (0.4, 4.6) 2.2 (0.1, 4.3) 
2nd trimester average rate of GWG, 
     per 0.3 kg/week increase 0.4 (0.3) 0.1 (-2.5, 2.6) -0.07 (-2.8, 2.6) 
Total rate of GWG up to GDM screening, 
     per 0.2 kg/week increase 0.3 (0.2) 2.0 (0.01, 4.0) 1.8 (-0.3, 4.0) 
Adequacy of GWG up to GDM screening N (%) β (95% CI) β (95% CI) 
     Inadequate 110 (26.6) -3.0 (-10.1, 4.0) -3.5 (-10.4, 3.4) 
     Adequate 78 (18.9) ref ref 
     Excessive 225 (54.5) 1.9 (-4.4, 8.1) 0.3 (-5.8, 6.3) 
GWG = gestational weight gain 
Missing: 20 women missing 1st and 2nd trimester rates of gain 
1Adjusted for pre-pregnancy BMI, age, parity, race/ethnicity, smoking, marital status, annual 
family income, education, family history of diabetes, gestational age of GDM screening 
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Table 6. Mean post-load glucose concentration by rate of gestational weight gain in first and second trimesters of 
pregnancy1, n = 393. 
1st trimester 2nd trimester N (%) Mean (SD) 
glucose 
p-value2 
< Mean < Mean 110 (28.0) 97.5 (22.5) ref 
< Mean ≥ Mean 83 (21.1) 95.4 (21.5) 0.56 
≥ Mean < Mean 89 (22.7) 103.7 (27.8) 0.07 
≥ Mean ≥ Mean 111 (28.2) 102.1 (25.5) 0.16 
Overall test for interaction 0.07 
1Mean rates of GWG rate: 1st trimester = 0.1 kg/week; 2nd trimester  = 0.4 kg/week 
2Student’s t-test for categories based on mean, Wald test for overall test of interaction 
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Table 7. Association between maternal blood glucose < 24 weeks gestation and waist circumference, biceps and 
triceps skinfold thickness at < 13 weeks gestation, n = 214 
Measurement Mean (SD) Unadjusted 
β (95% CI) 
Adjusted1 
β (95% CI) 
Biceps skin fold (mm), 
     per 8.6 mm increase 
14.6 (8.6) 5.1 (1.8, 8.3) 4.3 (0.2, 8.5) 
Triceps skin fold (mm),  
     per 11.7 mm increase 
25.9 (11.7) 5.9 (2.6, 9.1) 4.3 (0.2, 8.5) 
Waist circumference (cm),  
     per 26.8 cm increase 
99.9 (26.8) 4.5 (1.3, 7.8) 3.0 (-0.7, 6.8) 
1Adjusted for pre-pregnancy BMI, age, parity, race/ethnicity, education, and family history of 
diabetes 
 
 
60 
 
5.0  THE ASSOCIATION BETWEEN PRE-PREGNANCY OBESITY AND 
MATERNAL NUTRITIONAL BIOMARKER STATUS DURING PREGNANCY: A 
PRINCIPAL COMPONENT ANALYSIS 
5.1 ABSTRACT 
Pre-pregnancy obesity has been associated with an increased risk of a variety of adverse birth 
and pregnancy outcomes. Poor maternal essential fatty acid (EFA) and micronutrient status 
during pregnancy may contribute to these associations. However, these relationships have not 
been well researched in pregnancy. We assessed the association between maternal pre-pregnancy 
body mass index (BMI) and maternal micronutrient and EFA status in mid-pregnancy. Women 
(n=129) provided non-fasting blood samples at ≤20 weeks gestation that were assayed for red 
blood cell EFA, plasma folate, plasma ascorbic acid, serum retinol, serum 25-hydroxyvitamin D, 
serum α-tocopherol, plasma homocysteine, serum soluble transferrin receptors, and serum 
carotenoids. Principal component analysis of these biomarker measures was used to construct 
three nutritional components: an EFA component, a Micronutrient component, and a Carotenoid 
component. After adjustment for parity, race/ethnicity, and age, obese pregnant women were 3.0 
(95% CI: 1.1, 7.7) times as likely of being in the lowest tertile of the EFA component and 4.5 
(95% CI: 1.7, 12.3) times as likely of being in the lowest tertile of the Carotenoid component as 
their lean counterparts. We found no association between obesity and Micronutrient component 
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scores after confounder adjustment. Obese pregnant women may be vulnerable to having 
insufficient EFA and carotenoids concentrations, which may contribute to their elevated risk of 
adverse birth outcomes. 
5.2 INTRODUCTION 
In the United States, nearly a quarter of all pregnancies are complicated by pre-pregnancy 
obesity and the prevalence is increasing (S. Y. Kim, et al., 2007). Pregnant women who are 
obese are at higher risk of preeclampsia (Cedergren, 2004; Hauger, Gibbons, Vik, & Belizan, 
2008), gestational diabetes mellitus (Chu, et al., 2007), birth trauma, large-for-gestational age 
birth (Cedergren, 2004) and stillbirth (Cedergren, 2004; Cnattingius, Bergstrom, Lipworth, & 
Kramer, 1998) compared with their lean counterparts. Nevertheless, the mechanism by which 
obesity contributes to poor outcomes remains uncertain. 
Nutritional status during pregnancy may partially mediate the relation between pre-
pregnancy obesity and adverse pregnancy and birth outcomes. But the relationship between 
obesity and nutritional biomarkers has not been thoroughly researched in pregnancy. In non-
pregnant populations, obesity has been associated with insufficiencies of micronutrients, 
including vitamin E, vitamin C, vitamin D, folate, vitamin A and carotenoids (Andersen, et al., 
2006; Kimmons, et al., 2006). Some evidence suggests that obese women may require additional 
supplementation of folate and vitamin C to achieve similar serum concentrations as those of lean 
women (Block et al., 2008; Mojtabai, 2004). Obese individuals may also have lower levels of 
essential fatty acids (EFA) (Karlsson, et al., 2006; Kishino, et al., 2008) than lean patients. Taken 
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together, these studies suggest that obesity may have a negative effect on overall micronutrient 
and EFA status. Because these nutrients may play important roles in maternal and fetal health 
(IOM, 1990; Uauy, Hoffman, Peirano, Birch, & Birch, 2001), it is critical to explore these 
associations in pregnancy. 
The objective of our study was to evaluate the independent association between maternal 
adiposity, as measured by pre-pregnancy body mass index (BMI), and patterns of nutritional 
biomarkers at ≤ 20 weeks gestation. 
5.3 METHODS 
We conducted a secondary analysis of data from the Antidepressant Use during Pregnancy 
(ADUP) Study. ADUP is a prospective pregnancy cohort study of the effects of antidepressant 
use and major depressive disorder on pregnancy outcomes and child development (Wisner et al., 
2009).  Women were recruited at or before 20 weeks gestation after providing informed, written 
consent. Eligible women had singleton gestations. Women were excluded if they had psychosis, 
bipolar disorder, active substance use disorder (identified by self report or urine drug screen), 
gestational exposure to benzodiazepines or prescription drugs in the FDA-defined category of D 
or X (other than selective serotonin reuptake inhibitors) or chronic diseases (such as insulin-
dependent diabetes). At enrollment, women reported their pre-pregnancy weight and 
sociodemographic information, were measured for height, and provided a non-fasting blood 
sample. Blood samples were assayed for red blood cell EFA, plasma folate, plasma ascorbic 
acid, serum retinol, serum 25-hydroxyvitamin D, serum α-tocopherol, plasma homocysteine, 
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serum ferritin, serum soluble transferrin receptors, and serum carotenoids (described in detail 
below).  The study was approved by the University of Pittsburgh Institutional Review Board. 
The ADUP study recruited women from 2000-2007. In 2004, the study protocol was 
modified to include nutrition measures, including nutritional biomarker assessment in maternal 
blood. Of the 197 eligible women interviewed from 2004-2007, 130 (66%) provided a non-
fasting blood sample at ≤20 week that was processed for a full panel of nutritional biomarkers. 
We excluded one woman with missing data for pre-pregnancy weight.  Our final analytic sample 
was 129 women.  There were no meaningful differences between women included and excluded 
from the analysis on maternal characteristics, including race (80% versus 74% white race, p = 
0.31), education (63% versus 56% college-educated, p = 0.35), and smoking (15% versus 16% 
smokers, p = 0.79). 
Measures. General maternal adiposity before conception was measured using pre-
pregnancy BMI [weight (kg)/height (m)2], which was based on self-reported pre-pregnancy 
weight and measured height.  Because only 4 women in the sample were underweight (BMI 
<18.5 kg/m2), we categorized women into 3 groups: lean (<25 kg/m2), overweight (25.0-29.9 
kg/m2), and obese (≥30 kg/m2) ("Clinical Guidelines on the Identification, Evaluation, and 
Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of 
Health," 1998).   
We assayed maternal non-fasting blood samples drawn at ≤20 weeks’ gestation for 
biomarkers of nutritional status. The methods used to assay the nutritional biomarkers in our 
study have been published in detail previously (Tomedi, Bogen, Hanusa, Wisner, & Bodnar, in 
press) and are described here briefly. Blood samples were immediately put on ice and wrapped 
in foil. They were processed within 2 hours of blood draw. Serum, plasma, and red cells were 
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stored at -80°C in amber vials. Lipids were extracted from red blood cells (Bligh & Dyer, 1959) 
and quantified using gas chromatograph (Perkin Elmer Clarus 500). Although a total of 29 EFAs 
were quantified, we included only the three EFAs of greatest interest to maintain ease of 
interpretability. The red blood cell EFAs used in this analysis were docosahexaenoic acid 
(DHA), eicosapentaenoic acid (EPA), and arachidonic acid (AA). The inter-assay coefficients of 
variation (CV) were 14.4% for DHA, 4.2% for EPA (4.2%), and 5.5% for AA. Plasma folate was 
measured by a quantitative sandwich enzyme immunoassay technique (Roche Diagnostics, 
Indianapolis, IN) which has a CV of 2.0-3.9%. Concentrations of total homocysteine in plasma 
were determined by an enzymatic assay (Roche Diagnostics, Indianapolis, IN).  The CV for this 
assay was 2.1-5.3%. Plasma ascorbic acid (vitamin C) concentrations were determined by high-
performance liquid chromatography (HPLC) (Rumelin, et al., 1999), and the CV was 5.5%. 
Maternal vitamin D status was assessed using serum 25-hydroxyvitamin D [25(OH)D]. Serum 
25(OH)D was measured using an enzyme-linked immunosorbent assay (IDS, Tyne, United 
Kingdom) and validated against HPLC results (Bodnar, Simhan, et al., 2007). The ELISA assay 
had a CV of <10.0%. Iron status was assessed using serum ferritin and serum soluble transferrin 
receptor (sTfR) concentrations. Serum ferritin levels were analyzed using an immunoradiometric 
assay with I-125 labeled anti-ferritin antibody in a kit obtained from DPC (catalog # IKFE1, Los 
Angeles, CA). The CV was 16.4%. Total sTfR levels were measured using an ELISA from by 
R&D Systems (Minneapolis MN).  The CV was 8.5-17%. The quantification of serum 
carotenoids (β-carotene, lycopene, lutein+zeanthin, and β-cryptoxanthin), α-tocopherol (vitamin 
E), and retinol (vitamin A) were determined by HPLC (Armstrong, 1998). The CV’s were 6.0% 
for serum α-tocopherol, 8.0% for serum retinol, 12.0% for serum lutein + zeaxanthin, 11.0% for 
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serum β-cryptoxanthin, 9.0% for serum lycopene, and 11.0% for serum β-carotene. All samples 
were analyzed in duplicate and in a blinded fashion. 
Women identified their race/ethnicity as non-Hispanic white, non-Hispanic African 
American and other, but because only four women self identified as “other”, we combined the 
African American and the “other” groups into a non-white category for analysis. Women were 
categorized as nulliparous or as having a previous live birth. A diagnosis of major depressive 
disorder was made using the Structured Clinical Interview for DSW-IV (First et al., 1996). 
Educational status was defined as having less than a high school education, some college, college 
degree and post-graduate education. Women were classified as unemployed or employed (which 
included women who worked full time, part time, or occasionally). For marital status, “married” 
included married or living as married and “unmarried” included single, separated, widowed and 
divorced. Women were classified as current smokers if they smoked at all during pregnancy or 
non-smokers if they did not. 
Statistical Analysis. We used Pearson chi-square tests and Student’s t-tests to determine 
differences in maternal characteristics by pre-pregnancy BMI categories. To describe skewed 
biomarkers, we calculated geometric means and log-transformed biomarkers before statistical 
tests were performed. We conducted a principal component analysis on the fifteen untransformed 
maternal dietary biomarkers listed above.  Principal components analysis is a statistical method 
that combines many correlated variables and calculates a smaller number of components that 
explain much of the variation in the correlated variables (Kline, 1994).  We used Spearman's rho 
correlation coefficients because many of the biomarkers exhibited skewed distributions. 
Components were orthogonally rotated using the varimax method to account for correlation 
between components. We used eigenvalues, scree plots, and the interpretability of the solution to 
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examine solutions for two to eight components, and three components were chosen.  Nutritional 
biomarkers were considered to be loaded onto a component if the rotated component pattern 
value was greater than or equal 0.3. Serum ferritin did not load on any of the final components 
and, therefore, was not included in the final analysis. The estimated component scores were 
computed using a regression method. Component scores were categorized based on tertiles of the 
distribution. 
Multivariable logistic regression was used to assess the independent associations between 
pre-pregnancy BMI and the likelihood of being in the lowest tertile of the each nutritional 
component.  Potential confounders were maternal age, race/ethnicity, parity, education, marital 
status, smoking status, employment and depression. We defined confounding as a greater than a 
10% change in the odds ratio after excluding the covariate from the full model. In the EFA 
component model none of the covariates met this definition of confounding. In the micronutrient 
component model parity, race/ethnicity, and age met this definition of confounding. In the 
carotenoid component model only parity and race/ethnicity were confounders. To maintain 
comparability across models, parity, race/ethnicity, and age were included in all three of the final 
models. Data were analyzed using STATA software version 11.0 (StataCorp, College Station, 
TX). 
5.4 RESULTS 
The women in this cohort were primarily well-educated, non-Hispanic white, married, non-
smokers and employed (Table 8). The mean (SD) pre-pregnancy BMI was 26.6 (6.0) kg/m2.  
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About half (49.6%) of women were lean, 22.5% were overweight, and 27.9% were obese. Obese 
women were less likely to have a college degree and more likely to be nulliparous and depressed 
than lean women.  Maternal age, race/ethnicity, marital status, smoking, and employment did not 
significantly differ by pre-pregnancy BMI category. 
In unadjusted analysis, women who were overweight before pregnancy had lower mean 
plasma folate, plasma ascorbic acid, serum β-carotene and serum β-cryptoxanthin than lean 
pregnant women (Table 9). Compared with lean women, obese pregnant women had lower mean 
red cell DHA, red cell AA, plasma ascorbic acid, serum 25(OH)D, serum β-carotene, serum 
lutein + zeaxanthin, and serum β-cryptoxanthin concentrations and higher mean sTfR 
concentrations. Red cell EPA, serum retinol, serum α-tocopherol, plasma homocysteine, and 
serum lycopene did not differ by pre-pregnancy BMI category. 
Principle component analysis of the nutritional biomarkers resulted in three components.  
These components were assigned names based on the biomarkers that loaded heavily on the 
component and each represents biologically meaningful correlations between biomarkers.  
Component 1 was named “Essential Fatty Acids,” component 2 was named “Micronutrients,” 
and component 3 was named “Carotenoids” (Table 10). Although, β-carotene loaded on to both 
the Micronutrient and the Carotenoid components, for this analysis we will consider it to be a 
part of the Carotenoid component. 
As pre-pregnancy BMI category increased, the percent of women in the lowest tertile of 
each nutritional component increased (Figure 7). In unadjusted analysis, obese women had 
significantly greater odds of being in the lowest tertile of all three nutritional components (Table 
11). After adjustment for parity, race/ethnicity, and maternal age, obese pregnant women were 
three times as likely to be in the lowest tertile of the EFA component, and nearly five times as 
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likely to be in the lowest tertile of the carotenoid component as lean pregnant women. After 
adjustment, there was no association between obesity and micronutrient component scores. 
There was no relation between pre-pregnancy overweight and any of the nutritional components 
before or after adjustment. 
5.5 DISCUSSION 
Using three general nutritional components describing an array of nutritional biomarkers, we 
found that a larger percentage of obese women were in the lowest tertile of the EFA, 
Micronutrient, and Carotenoid components than lean women at ≤20 weeks gestation. After 
adjustment for maternal characteristics, pre-pregnancy obesity remained associated with poorer 
EFA and Carotenoid component scores. 
 It is important to understand the relationship between pre-pregnancy obesity and 
nutritional patterns during pregnancy. More than 20% of American women are obese prior to 
pregnancy (S. Y. Kim, et al., 2007) and high micronutrient and EFA concentrations are 
associated with improved birth outcomes (Helland, Smith, Saarem, Saugstad, & Drevon, 2003; 
Kramer et al., 2009; van Goor et al., 2010). Nutritional interventions in other high risk 
populations have been successful in improving maternal nutritional status (Imhoff-Kunsch, Stein, 
Villalpando, Martorell, & Ramakrishnan, 2011; Piirainen, Isolauri, Lagstrom, & Laitinen, 2006), 
suggesting that maternal nutritional status can be modified. However, very few researchers have 
explored micronutrient and EFA status of obese women in pregnancy. Further, we are unaware 
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of any other study to have examined obesity relative to a wide range of maternal biomarkers 
summarized using principal component analysis methods.  
 Our results showing poorer carotenoid status among obese women compared with lean 
women are in agreement with several studies in non-pregnant populations (Chai et al., 2010; 
Ford, et al., 2002; Galan, et al., 2005; Neuhouser, et al., 2001; Wallstrom, et al., 2001). For 
example, in a cross-sectional analysis of Third National Health and Nutrition Examination 
Survey (NHANES) that included 4,512 non-pregnant, pre-menopausal women, both obese and 
overweight women were significantly more likely to be in the lowest 20th percentile of a sum of 
carotenoid concentrations (Kimmons, et al., 2006). In a longitudinal study of over 3,000 young 
adults, Anderson et al. evaluated the independent effect of obesity on future carotenoid status, 
and found that, in non-smokers, obese patients had 12-34% (p < 0.01) lower carotenoid 
concentrations seven years later compared with patients with a BMI below 22 kg/m2 at baseline 
(Anderson, et al., 2003). 
Our result that pre-pregnancy BMI is associated with an EFA component (composed of 
three polyunsaturated EFAs) is supported by a small (n = 14) cross-sectional analysis of obese 
versus non-obese adolescent females. In this study, researchers found that obese girls had a 
significantly lower sum of polyunsaturated EFAs then normal weight girls [mean (SD): 34.9 
(0.9) versus 37.0 (1.7) mole %, p < 0.05] (Karlsson, et al., 2006).  Obesity may decrease 
concentrations of EFAs, but poor EFA status may also increase the likelihood of being obese. 
For example, in a prospective analysis of 1,250 mother-child pairs, a higher sum of umbilical 
cord plasma DHA and EPA concentrations was associated with lower adiposity at three years of 
age in the infant [OR = 0.09 (95% CI: 0.02, 0.52 for obesity)] (Donahue et al., 2011).  
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Concentrations of AA in umbilical cord plasma were not associated with later adiposity. Further 
study is required to better understand the directionality of these associations. 
We found that pre-pregnancy obesity was not related to an increased likelihood of being 
in the lowest tertile of the micronutrient component after adjustment for maternal characteristics.  
It is difficult to directly compare our results to those of previous studies because we used a 
measure of overall micronutrient status, and many previously published studies presented one or 
two specific biomarkers. In one cross-sectional analysis of multiple micronutrients among non-
pregnant, pre-menopausal women, researchers found that obese women are more likely to have 
low levels of vitamin E, vitamin C, vitamin D and serum folate than non-obese women 
(Kimmons, et al., 2006). They found no association between BMI and vitamin A and red blood 
cell folate. In another study examining multiple micronutrients, 76 obese women had lower 
concentrations of serum retinol, serum ascorbic acid, serum 25(OH)D, and serum alpha-
tocopherol than 30 lean women, but serum folic acid concentrations were not different (Aasheim, 
Hofso, Hjelmesaeth, Birkeland, & Bohmer, 2008). Studies of single nutrients examined in non-
pregnant populations by obesity status have reported strong associations between BMI and 
micronutrients such as vitamin D (Arunabh, et al., 2003; Holvik, et al., 2005; Nesby-O'Dell, et 
al., 2002; Parikh, et al., 2004; Snijder, et al., 2005) and folate (Mahabir, et al., 2008; Mojtabai, 
2004; Tungtrongchitr, et al., 2003). But studies of other nutrients, such as α-tocopherol, have 
been inconsistent (Chai, et al., 2010; Galan, et al., 2005; Neuhouser, et al., 2001). Additionally, 
there is evidence that maternal obesity increases the likelihood of poor vitamin D (Bodnar, 
Catov, et al., 2007) and folate (Han, Ha, Park, Kim, & Lee, 2010) status during pregnancy.  
The dissimilarities between our micronutrient findings and those of previous studies are 
likely due to major differences in our study populations and differences in our outcome 
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measurement. For example, Kimmons and colleagues studied a large, nationally representative 
sample of non-pregnant, non-lactating women compared with our small study of well-educated 
pregnant women. Prenatal vitamin use is common among pregnant women (Yu, Keppel, Singh, 
& Kessel, 1996), and regular use of prenatal vitamins may confound or modify the association 
between BMI and blood micronutrient concentrations. Unfortunately, neither our study, nor that 
of Kimmons et al. incorporated data on vitamin and mineral supplementation to test this 
hypothesis. Similar to many previous studies, we found that obese women had lower mean serum 
25(OH)D than lean women. When 25(OH)D was included into a Micronutrient component, our 
primary outcome measure, there was no difference between obese women and lean women. 
There are several potential mechanisms may explain an association between high BMI 
and poor nutritional biomarker status. Obese women may have a poor diet quality (Laraia, 
Bodnar, & Siega-Riz, 2007), which may account for low biomarker concentrations. Many of the 
micronutrients that loaded on to the Micronutrient component are present in prenatal vitamins, 
but the EFAs in the EFA Component and the carotenoids that loaded on to the carotenoid 
component are not always included in prenatal supplements. If obese women in our cohort were 
taking prenatal supplements, but consumed diets poor in fruits and vegetables and EFAs, this 
may account for our results. There is also the possibility that excess fat may have a direct effect 
on nutritional biomarker status. For example, obesity may alter the absorption and metabolism of 
vitamin D (Blum, et al., 2008; Moan, et al., 2009; Wortsman, et al., 2000). Other fat soluble 
nutrients, such as carotenoids, may also be sequestered by excess fat and rendered biologically 
unavailable. Lastly, obesity may contribute to decreased concentrations of antioxidants, such as 
carotenoids, in pregnant women by creating an increased need for antioxidants by creating an 
excess of oxidative stress (Keaney et al., 2003). 
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Several limitations should be taken into consideration when reviewing our results. Pre-
pregnancy BMI is a general measure of adiposity that does not provide information on type or 
distribution of fat, which may be more informative for micronutrient and EFA status. Obesity is 
associated with an increase in total blood volume (Alpert, 2001), which could artificially lower 
micronutrient and EFA concentrations in the blood. Unfortunately, measures of blood volume 
were not collected in this study and we were unable to control for this possible covariate. 
Additionally, using BMI calculated from self-reported pre-pregnancy weight may have led to 
misclassification (Bodnar, Siega-Riz, Simhan, Diesel, & Abrams, 2010). Data on supplement use 
and dietary intake were not available, so we could not consider their confounding or modifying 
effects on the associations we reported. Ferritin concentrations did not load onto the 
Micronutrient component, and was not included in our analysis. This may be because ferritin 
concentrations can reflect inflammation as well as dietary intake and therefore may have not 
correlated as well with the other micronutrient concentrations. Women with chronic diseases 
were excluded from our study, which meant that women included in our analysis were generally 
healthy. Our study had a relatively small sample size of primarily white, well-educated, non-
smoking women. The population’s small size and homogeneity led to imprecise estimates and 
reduced generalizability. Furthermore, because we did not collect nutritional biomarkers before 
pregnancy, our understanding of the temporality of the relationship between BMI and nutritional 
status is limited. Concentrations of nutritional biomarkers were generally high in our cohort, 
decreasing the variation of our outcome measurement. As a consequence, our observed effect 
sizes are likely closer to the null than those that we would have seen if our cohort had a wider 
range of nutritional biomarker values.  
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Major strengths of our study include an analysis of a wide array of nutritional biomarkers 
measured in mid-pregnancy and the use of principle components analysis of the biomarkers to 
account for the inherent correlation between nutrients and reduce the likelihood of type 1 error 
due to multiple comparisons. In the future, large, prospective studies with a full panel of 
nutritional biomarkers and detailed information on distribution of fat mass, diet and supplement 
use during pregnancy are needed to confirm or refute our results. 
Our results suggest that women who are obese before pregnancy may be a high-risk 
group for having poor EFA and carotenoid status during pregnancy. Maternal carotenoid and 
EFA concentrations have been associated with important pregnancy and birth outcomes such as 
neurological development and preterm delivery, and effective interventions that improve 
nutritional status are available. A better understanding of the effect of pre-pregnancy obesity on 
maternal micronutrient and EFA status may lead to more specific nutritional interventions to 
improve pregnancy and birth outcomes in this at-risk population. 
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5.6 FIGURES AND TABLES 
 
Figure 7. Percent of pregnant women in each tertile of the Fatty acids, Micronutrients, and Carotenoids 
components, by pre-pregnancy BMI. Tertile 1 represents the lowest component scores and tertile 3 represents the 
highest component scores, N =129 
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Table 8. Maternal characteristics of the ADUP population, overall and stratified by pre-pregnancy BMI. 
Characteristic Total 
(N = 129) 
BMI < 25 
(n = 64) 
BMI 25-29.9 
(n = 29) 
BMI ≥ 30 
(n = 36) 
p-value1 
Age, mean (SD) 30.3 (5.6) 30.6 (5.8) 31.6 (4.4) 28.7 (5.9) 0.14 
Race/ethnicity, N (%)      
     White 103 (79.8) 56 (87.5) 23 (79.3) 24 (66.7)  
     African American 22 (17.1) 6 (9.4) 6 (20.7) 10 (27.8)  
     Other 4 (3.1) 2 (3.1) 0 (0.0) 2 (5.6) 0.10 
Parity, N (%)      
     0 43 (33.3) 33 (51.6) 23 (79.3) 30 (83.3)  
     1-6 86 (66.7) 31 (48.4) 6 (20.7) 6 (16.7) <0.01 
Educational status, N (%)      
     ≤ High School 23 (17.8) 5 (7.8) 4 (13.8) 14 (38.9)  
     Some college 25 (19.4) 12 (18.8) 4 (13.8) 9 (25.0)  
     College degree 45 (34.9) 25 (39.1) 9 (31.0) 11 (30.6)  
     Post-graduate education 36 (27.9) 22 (34.4) 12 (41.4) 2 (5.6) <0.01 
Married, N (%)      
     Married 95 (73.6) 48 (75.0) 25 (86.2) 22 (61.1)  
     Unmarried 34 (26.4) 16 (25.0) 4 (13.8) 14 (38.9) 0.07 
Smoker, N (%)      
     Non-smoker 110 (85.3) 56 (87.5) 27 (93.1) 27 (75.0)  
     Smoker 19 (14.7) 8 (12.5) 2 (6.9) 9 (25.0) 0.10 
Employment status, N (%)      
     Employed 73 (56.6) 37 (57.8) 17 (58.6) 19 (52.8)  
     Unemployed 56 (43.4) 27 (42.2) 12 (41.4) 17 (47.2) 0.86 
Major depresssion2, N (%)      
     Not depressed 96 (74.4) 53 (82.8) 22 (75.9) 21 (58.3)  
     Depressed 33 (25.6) 11 (17.2) 7 (24.1) 15 (41.7) 0.03 
BMI = body mass index 
1Based on a student’s t-test for maternal age and a chi-squared test for the other covariates 
2As measured by the Structured Clinical Interview for DSW-IV 
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Table 9. Mean1 maternal nutritional biomarkers at 20 weeks gestation, stratified by pre-pregnancy BMI 
Biomarker 
BMI<25 
(n = 64) 
BMI 25-29 
(n = 29) p-value2 
BMI ≥ 30 
(n = 36) p-value 
Red cell DHA (%) 3.4 (2.7-4.4) 3.1 (2.2-4.2) 0.58 1.9 (1.3-2.7) <0.01 
Red cell AA (%) 13.0 (11.4-14.8) 12.9 (10.5-15.8) 0.95 9.3 (7.3-11.9) 0.01 
Red cell EPA (%) 0.33 (0.28-0.40) 0.28 (0.22-0.35) 0.30 0.25 (0.18-0.33) 0.06 
Plasma folate (ng/ml) 15.3 (13.6-17.2) 12.5 (10.7-14.6) 0.04 13.0 (11.3-15.1) 0.08 
Plasma ascorbic acid (µg/ml) 12.9 (12.1-13.7) 10.4 (8.7-12.4) 0.01 11.0 (9.7-12.4) 0.03 
Serum retinol (µg/ml)  0.50 (0.48-0.53) 0.46 (0.43-0.50) 0.11 0.47 (0.43-0.51) 0.17 
Serum 25(OH)D (nmol/L) 88.5 (81.3- 96.3) 77.8 (63.1-96.0) 0.20 69.9 (59.0-82.9) 0.01 
Serum α-tocopherol (µg/ml) 0.07 (0.06-0.07) 0.07 (0.06-0.08) 0.72 0.07 (0.06-0.07) 0.47 
Serum β-carotene (µg/ml) 0.14 (0.10-0.19) 0.06 (0.04-0.11) 0.01 0.04 (0.03-0.06) <0.01 
Serum homocysteine (µmol/L) 2.3 (2.1-2.6) 2.3 (2.1-2.6) 0.94 2.3 (1.9-2.7) 0.75 
Serum sTfR (nmol/L) 14.5 (13.7-15.4) 15.9 (14.5-17.4) 0.09 16.3 (14.9-17.7) 0.03 
Serum lutein+zeaxanthin (µg/ml) 0.14 (0.12-0.17) 0.12 (0.10-0.14) 0.17 0.08 (0.06-0.10) <0.01 
Serum β-cryptoxanthin (µg/ml) 0.10 (0.08-0.13) 0.06 (0.04-0.09) 0.02 0.05 (0.04-0.07) <0.01 
Serum lycopene (µg/ml)  0.30 (0.26-0.35) 0.32 (0.27-0.37) 0.76 0.28 (0.23-0.34) 0.41 
BMI = body mass index; DHA = docosahexaenoic acid; AA = arachidonic acid; EPA = eicosapentaenoic acid; 25(OH)D = 25-
hydroxyvitamin D; sTfR = soluble transferrin receptors 
1Geometric means, all values presented as mean (95% CI) 
2Student’s t-test, biomarkers log transformed before tests were performed, BMI < 25 is the reference group 
77 
 
 
Table 10. Rotated pattern matrix of maternal dietary biomarkers. Biomarkers loaded on to three components: a fatty 
acid, a micronutrient, and a carotenoid component. 
 Component 
Biomarker  Fatty Acids Micronutrients Carotenoids 
Red cell docosahexaenoic acid  0.94 - - 
Red cell arachidonic acid  0.87 - - 
Red cell eicosapentaenoic acid 0.66 - - 
Plasma folate  - 0.55 - 
Plasma ascorbic acid  - 0.55 - 
Serum retinol  - 0.51 - 
Serum 25-hydroxyvitamin D  - 0.47 - 
Serum α-tocopherol  - 0.32 - 
Serum β-carotene  - 0.30 0.68 
Serum homocysteine  - -0.58 - 
Serum soluble transferrin receptors - -0.56 - 
Serum lutein+zeaxanthin  - - 0.77 
Serum β-cryptoxanthin  - - 0.66 
Serum lycopene  - - 0.52 
Factor analysis on 14 biomarkers; reported as |factor loadings| ≥ 0.30. 
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Table 11. Association between pre-pregnancy BMI and probability of being in the lowest tertile1 of fatty acid, 
micronutrient and carotenoid components, N = 129 
 Nutrient component, OR (95% CI) 
 Fatty acid Micronutrient Carotenoid 
Unadjusted model    
          BMI < 25 ref ref ref 
          BMI: 25-29.9 1.6 (0.6, 4.1) 2.5 (1.0, 6.5) 1.4 (0.5, 3.7) 
          BMI ≥ 30 2.7 (1.1, 6.4) 3.6 (1.5, 8.6) 5.0 (2.1, 12.2) 
Adjusted model2    
          BMI<25 ref ref ref 
          BMI: 25-29.9 1.5 (0.6, 4.1) 1.8 (0.6, 5.7) 1.4 (0.5, 4.3) 
          BMI ≥ 30 3.0 (1.1, 7.7) 1.5 (0.5, 4.5) 4.5 (1.7, 12.3) 
BMI = body mass index 
1Lowest tertile compared to the combined middle and highest tertiles of nutrient components 
2Adjusted for parity, race/ethnicity, age. Further adjustment for other covariates had no 
meaningful impact on the findings. 
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6.0  THE ROLE OF MATERNAL VITAMIN D STATUS IN THE DEVELOPMENT 
OF GESTATIONAL HYPERGLYCEMIA 
6.1 ABSTRACT 
Maternal vitamin D status may play an important role in glucose homeostasis during pregnancy. 
The objective of our study was to estimate the effects of early pregnancy 25-hydroxyvitamin D 
[25(OH)D] concentrations on maternal post-load glucose concentration at GDM screening. 
Pregnant women (n = 484, 63% black, 57% with BMI≥25) enrolled in a cohort study at <16 
weeks gestation, and blood samples were assayed for serum 25(OH)D. At 24-28 weeks gestation, 
post-load glucose concentration was measured using a 50-g 1-hour oral glucose tolerance test. 
Smoking during pregnancy modified the association between vitamin D and glucose 
concentration. Among non-smokers, each 21-nmol/L increase in serum 25(OH)D was associated 
with a 4.1 (95% CI: 0.9, 7.2)-mg/dl increase in maternal post-load glucose concentration after 
adjustment for race/ethnicity, age, pre-pregnancy BMI, and season of blood sample. Among 
smokers, each 21-nmol/L increase in serum 25(OH)D was associated with a 7.3 (95% CI: 11.4, 
3.1)-mg/dl decrease in maternal post-load glucose concentration after confounder adjustment. In 
this cohort, vitamin D status was positively associated with maternal glucose concentrations in 
non-smokers and negatively associated with maternal glucose in smokers. Further research is 
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needed to understand the relationship between vitamin D status and maternal glucose 
concentrations among smokers and non-smokers during pregnancy. 
6.2 INTRODUCTION 
Gestational diabetes mellitus (GDM), defined as glucose intolerance with onset or first 
recognition during pregnancy, occurs in 4% of pregnancies (Getahun, et al., 2008). GDM is a 
major risk factor for a variety of pregnancy complications, including macrosomia and birth 
trauma (Henriksen, 2008; Jevitt, 2005). Importantly, maternal hyperglycemia below the 
threshold of GDM has also been shown to have a linear relationship with adverse birth outcomes, 
such as preeclampsia, shoulder dystocia, and birth weight > 90th percentile (Metzger, et al., 
2008). Nevertheless, the etiology of maternal hyperglycemia remains obscure. 
Vitamin D status may be associated with maternal hyperglycemia. Vitamin D is a 
secosteroid, obtained through diet and cutaneous synthesis after sunlight exposure (Holick, 
2004). Vitamin D deficiency inhibits the secretion of insulin in animal models (Draznin, et al., 
1988; Norman, et al., 1980; Sooy, et al., 1999) and has been associated with glucose 
concentrations in non-pregnant populations (Nikooyeh et al., 2011; von Hurst, Stonehouse, & 
Coad, 2010) has prompted several investigations of the role of vitamin D in the development of 
GDM. Nevertheless, studies are limited and results have been inconclusive (Clifton-Bligh, et al., 
2008; Farrant, et al., 2009; Maghbooli, et al., 2007; C. Zhang, et al., 2008). Because maternal 
hyperglycemia is associated with poor outcomes, studying its association with a modifiable risk 
factor such as vitamin D is important for public health.  
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The objective of our study was to determine the independent association between early 
maternal vitamin D status, as measured by serum 25(OH)D and mid-pregnancy maternal post-
load glucose concentration. 
6.3 METHODS 
We used data from the Study of Nutrition and Pregnancy (SNAP). SNAP is an ongoing 
prospective pregnancy cohort study conducted in the prenatal clinics at Magee-Womens Hospital 
(Pittsburgh, PA). Pregnant women attending the clinics are primarily low-income, publically 
insured, and approximately 50% African American. Eligible women had singleton pregnancies 
and had self reported their race/ethnicity as non-Hispanic black or non-Hispanic white. Patients 
were excluded if they had pre-gestational diabetes, vaginal bleeding, thrombophilias, chronic 
hypertension requiring medication, current or planned cervical cerclage, compromised immune 
system, autoimmune diseases, or known use of illegal drugs or controlled substances. All 
enrolled participants provided informed, written consent. The study was approved by the 
University of Pittsburgh Institutional Review Board. 
A total of 672 eligible pregnant women were enrolled at < 16 weeks’ gestation between 
June 2003 and November 2009. At enrollment, women completed a structured interview that 
included questions on socio-demographic factors and medical history. For this analysis, we 
excluded women who had a spontaneous or therapeutic abortion (n = 79) or had biologically 
implausible 25(OH)D measurements (n = 5). A total of 55 women were missing 25(OH)D 
measurements because they lacked sufficient serum volume to assay for 25(OH)D. An additional 
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49 women were excluded from our analysis because they lacked post-load glucose concentration 
data. Mean post-load glucose concentrations and maternal characteristics did not significantly 
differ between women included and excluded from the analyses (data not shown). A total of 484 
women were included in the final analyses. 
 50-g 1-hour oral glucose challenge test was performed as part of routine clinical care at 
approximately 24-28 weeks gestation to screen for GDM. Women with post-load glucose 
concentration values >135 mg/dL additionally received a 3-hour 100-gram oral glucose tolerance 
test. All glucose concentrations were abstracted from medical records. Maternal hyperglycemia 
was defined as high blood sugar during pregnancy (Metzger, et al., 2008). We defined women 
with post-load glucose concentration values ≥ 180 mg/dL, or 2 or more abnormal 3-hour 100-
gram oral glucose tolerance results as having GDM (Carpenter & Coustan, 1982). A total of 45 
women whose health care provider classified them as high risk underwent early screening (< 24 
weeks gestation). We conducted a sensitivity analysis to determine the influence of excluding 
these women from our analysis and found no significant difference between the models (data not 
shown). Therefore, women with early GDM screening were retained in our sample. 
Concentrations of serum 25(OH)D were quantified using a DiaSorin radioimmunoassay 
(RIA). The RIA detects 100% of 25(OH)D2 and 100% of 25(OH)D3. Maternal serum samples 
were stored in aliquots at –80°C until they were analyzed for 25(OH)D [25(OH)D2 + 
25(OH)D3]. The interassay coefficient of variation was 9.5%. The detectable limits for the RIA 
are 3.75 to 250 nmol/L. None of the samples of 25(OH)D included in our analysis fell outside 
this range. We defined vitamin D sufficiency as ≥ 50 nmol/L and also explored a cut-off of <40 
nmol/L (IOM, 2011).  
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Maternal demographics and pre-pregnancy weight were obtained by self-report at 
enrollment, and family history of diabetes was abstracted from medical records after delivery. 
Women were classified as current smokers if they smoked any cigarettes during pregnancy or 
non-smokers if they did not. Beginning in July of 2006, exhaled carbon monoxide (CO) 
measurements were measured in the SNAP study to confirm self-reported smoking status (Pearce 
& Hayes, 2005) (n = 122). Exhaled CO concentration was measured using a CO breath analyzer 
(Micro CO; Micro Medical Limited; Chatham, Kent, England) that was sensitive to CO 
concentrations from 1 to 500 ppm (by volume). Participants were asked to hold their breath for 
15 seconds and then exhale slowly with a constant flow into the analyzer, and this measurement 
was recorded.  
Women were categorized as nulliparous or multiparous. For marital status, women were 
categorized as married if they were currently married and unmarried otherwise (single, separated, 
widowed and divorced). Annual family income was separated into < $10,000, $10,000-25,000, 
$25,000-50,000, and ≥$50,000. Women were classified as unemployed or employed (which 
included women who worked full time, part time, or occasionally). Educational status was 
defined as having a high school degree or less, a college degree, or a graduate/professional 
degree. A family history of diabetes included any reported history of a family member having 
type 1 or type 2 diabetes mellitus. Pre-pregnancy BMI was calculated as self-reported pre-
pregnancy weight (kg) divided by measured height (m2). A BMI of <18.5 was defined as 
underweight, 18.5-24.9 as normal weight, 25.0-29.9 as obese, and 30+ as obese ("Clinical 
Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in 
Adults--The Evidence Report. National Institutes of Health," 1998). Season of blood sampling 
was categorized as by winter (December-May) or summer (June-November). 
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We analyzed maternal post-load glucose as a continuous outcome variable because 
maternal hyperglycemia, even below the threshold of GDM diagnosis, is strongly associated with 
adverse pregnancy outcomes (Metzger, et al., 2008). The Student’s t-test and Pearson chi-square 
test were used to determine the differences in post-load glucose and GDM status by maternal 
characteristics. The relationship of serum 25(OH)D concentration with post-load glucose 
concentration was assessed using locally weighted regression (lowess smoothing plots) 
(StataCorp, 2009). As no meaningful deviations from linearity were found, 25(OH)D was 
examined as a continuous variable in linear regression models assessing the independent 
association between 25(OH)D and post-load glucose. However, we also categorized 25(OH)D 
for ease of interpretation. Effect modification by race/ethnicity, pre-pregnancy BMI, and 
smoking were tested using the Wald test (α < 0.05). We assessed maternal age, parity, 
race/ethnicity, smoking status, marital status, annual family income, employment status, 
education, family history of diabetes, pre-pregnancy BMI, season of 25(OH)D sample and 
gestational age of 50-g 1-hour oral glucose challenge test as potential confounders. We defined 
confounding as a > 10% change in the adjusted beta coefficient after exclusion of the covariate 
from the full model. The following confounders met this definition: pre-pregnancy BMI, 
race/ethnicity, maternal age, and season of 25(OH)D sample. We conducted a post-hoc analysis 
of the effect modification of exhaled CO values on the relationship between vitamin D and 
maternal glucose concentrations in a sub-sample of women (n=122). Because of the small 
sample of women with exhaled CO values, we assessed CO as a continuous variable using a 
model that contained a continuous 25(OH)D variable, exhaled CO variable and interaction term 
[25(OH)D times exhaled CO]. Data were analyzed using STATA software version 11.0 
(StataCorp, 2009). 
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6.4 RESULTS 
The mean (SD) gestational age at enrollment was 9.3 (2.9) weeks’ gestation. The majority of 
women were young, unmarried, low-income, multiparous, African American and high-school 
educated (Table 12). Nearly half the women in the cohort smoked during pregnancy and more 
than a third were obese before pregnancy.  
 The mean (SD) 25(OH)D concentration in our cohort was 41.5 (21.4) nmol/L. A total of 
263 (54.3%) women had 25(OH)D concentrations < 40 nmol/L and 325 (67.2%) women had 
concentrations < 50 nmol/L. Low vitamin D status (25(OH)D < 50 nmol/L) was more prevalent 
in multiparous, African American, unmarried, high-school educated, and obese women as well as 
women whose blood was drawn in winter months (Table 12). Furthermore, African American 
women, unmarried women and high-school educated women had significantly lower mean 
glucose concentrations than their counterparts. Neither 25(OH)D insufficiency nor post-load 
differed by smoking status, annual family income, employment, and family history of diabetes. 
Women in our cohort were screened for GDM at approximately 26.7 (SD: 3.6) weeks 
gestation, and the mean (SD) post-load glucose concentration was 99.4 (24.9) mg/dl. Ten percent 
of the women in our cohort failed the GDM screening (post-load glucose concentrations ≥ 135 
mg/dl) and 2.5% were later diagnosed with GDM. In the total population, vitamin D deficiency 
was not significantly associated with mean post-load glucose concentrations, failed GDM 
screening (glucose concentration ≥ 135 mg/dl), or GDM diagnosis (Table 13). 
Smoking status during pregnancy modified the effect of effect of serum 25(OH)D on 
glucose concentrations (Figure 8, Table 14). Among non-smokers, there was a positive linear 
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relationship between early pregnancy serum 25 (OH) D concentrations and post-load glucose 
concentration.   
Each standard deviation (SD) increase in 25(OH)D concentration was associated with an 
approximately 4.1-mg/dL increase in post-load glucose concentrations after adjustment for pre-
pregnancy BMI, race/ethnicity, maternal age, and season of blood sampling. Concentrations of 
25(OH)D ≥ 50 nmol/L were associated with an approximately 7-mg/dl increase in post-load 
glucose concentrations after confounder adjustment. Results were similar when we used a cut-
point of 25(OH)D ≥ 40 nmol/L (data not shown).  
Conversely, among smokers, post-load concentrations decreased as 25(OH)D 
concentrations increased. Each SD increase in 25(OH)D concentration was associated with an 
approximately 7.3-mg/dl decrease in post-load glucose after adjustment. Levels of 25(OH)D ≥ 
50 nmol/L among smokers were associated with an approximately 13-mg/dl decrease in post-
load glucose concentration, with results when a cut-point of 25(OH)D ≥ 40 nmol/L was used 
(data not shown).  
In the sub-population of women with a measured exhaled CO, the mean (SD) of exhaled 
CO was 3.2 (4.0) ppm among self-reported non-smokers and 10.9 (6.9) ppm among self-reported 
smokers (p<0.05). To confirm the interaction of self-reported smoking, we tested this same 
interaction, post-hoc, using exhaled CO, a biomarker of smoking status. After accounting for the 
interaction between 25(OH)D and continuous exhaled CO, we observed that 25(OH)D had a 
positive relationship with glucose concentrations when exhaled CO values were zero, and a 
negative relationship with glucose concentrations as CO values increased. For example, among 
women who had a exhaled CO value of zero ppm, a woman who had a 25(OH)D concentration 
of 23 nmol/L would have a glucose concentration of 89.1 (95% CI: 79.8, 98.4) mg/dl, and if her 
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25(OH)D concentration increased to 58 nmol/L, then her glucose concentration would increase 
to 102.9 (95% CI: 95.4, 110.4) mg/dl (p = 0.01). However, among women who had an exhaled 
CO of 10 ppm (the mean for smokers), a woman who had a 25(OH)D concentration of 23 
nmol/L would have a glucose concentration of 99.3 (95% CI: 90.6, 108.0) mg/dl, and if her 
25(OH)D concentration increased to 58 nmol/L, then her glucose concentration would decrease 
to 97.9 (95% CI: 92.0, 103.9) mg/dl (p = 0.03). 
6.5 DISCUSSION 
In this cohort of African American and white pregnant women, the association between maternal 
serum 25(OH)D and post-load glucose concentrations was significantly modified by maternal 
smoking status. Among smokers, serum 25(OH)D concentrations in early pregnancy were 
inversely associated with mid-pregnancy post-load glucose concentration. In non-smokers, as 
25(OH)D concentrations increased, post-load glucose concentrations also increased. Both of 
these associations remained statistically significant after adjustment for measured confounders. 
In non-pregnant populations, there is a growing body of literature supporting an 
association between vitamin D status and glucose concentrations (Baynes, et al., 1997; Forouhi, 
et al., 2008; Isaia, et al., 2001; Nikooyeh, et al., 2011; von Hurst, et al., 2010). In intervention 
studies, a causal link between vitamin D insufficiency and impaired glucose is controversial in 
non-pregnant populations (Shapses & Manson, 2011). But some studies in non-pregnant 
populations support that treatment with vitamin D may improve glucose levels (Boucher, et al., 
1995; Forouhi, et al., 2008). Results of the few previous studies of vitamin D status and GDM 
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have been inconsistent. Cross-sectional studies have reported poorer vitamin D status among 
women with GDM compared with healthy pregnant women in unadjusted analysis  (Maghbooli, 
et al., 2007), as well as associations between vitamin D status and GDM that did not reach 
statistical significance (Farrant, et al., 2009) or fasting glucose after confounder adjustment 
(Clifton-Bligh, et al., 2008). These three studies measured vitamin D status at GDM screening or 
glucose concentration assessment, often in mid to late pregnancy and did not report smoking 
status. To our knowledge, only one study has assessed the association between vitamin D status 
early in pregnancy and GDM. In this nested case-control study women with vitamin D 
deficiency [25(OH)D < 20 ng/ml] at 16 weeks’ gestation were at a nearly 3-fold increased risk 
for GDM than women with  25(OH)D ≥ 20 ng/ml (C. Zhang, et al., 2008). This association was 
significant after adjustment for maternal age, race/ethnicity, family history of type 2 diabetes, 
and pre-pregnancy BMI. Our results may differ because we assessed continuous post-load 
glucose concentration in a predominately African American cohort with a high prevalence of 
smoking, and Zhang et al. studied overt GDM in a cohort of mostly non-smoking non-Hispanic 
white women. However, our results among non-smokers were not in agreement with the results 
found by Zhang et al. in their primarily non-smoking population.  
There are several potential mechanisms for poor maternal vitamin D status to increase the 
risk of maternal hyperglycemia. 1,25-hydroxyvitamin D, the hormonally active form of the 
vitamin, is required for the pancreas to release insulin (Kadowaki & Norman, 1985). 1, 25-
hydroxyvitamin 2D binds to receptors on the pancreatic β-cell and may regulate β-cell calcium 
homeostasis (Norman, et al., 1980; Sooy, et al., 1999). Also, vitamin D in the body ensures an 
adequate intracellular cytosolic calcium pool, which is essential for glucose uptake by insulin-
responsive tissues (Draznin, et al., 1988).  
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Our results that vitamin D status is positively associated with maternal glucose 
concentrations among non-smokers and negatively associated with glucose concentrations 
among smokers is not well supported by previous literature. To our knowledge, a positive linear 
relationship between maternal 25(OH)D and post-load glucose concentrations among non-
smokers has not been previously observed. In an attempt to resolve this difference in 
conclusions, we confirmed our findings with a biomarker of self-reported smoking status. The 
biomarker, exhaled CO, is also a marker of oxidative stress, suggesting a potential biological 
explanation for our results. We are only aware of one study that examined how smoking may 
modify the effect between vitamin D status and glucose concentration. In a population-based 
study of older, non-pregnant Norwegians, researchers found that, in both smokers and non-
smokers, there was no association between vitamin D and type 2 diabetes after adjustment for 
BMI (Grimnes et al., 2010). The possible mechanisms for positive association between vitamin 
D status and glucose concentrations that we observed among non-smokers are uncertain. It may 
be that the association between vitamin D and maternal glucose concentration differs in the 
presence of oxidative stress. Exhaled CO values are not only a biomarker of smoking status, but 
may also indicate oxidative stress among diabetics (Paredi, Biernacki, Invernizzi, Kharitonov, & 
Barnes, 1999). Therefore, our exhaled CO results suggest that vitamin D lowers glucose 
concentrations in the presence of oxidative stress, but raises glucose concentrations in the 
absence of oxidative stress. While this has not been well researched in vivo, in vitro cancer 
studies have suggested that metabolites of vitamin D may have antioxidant properties in some 
cell lines (Bao, Ting, Hsu, & Lee, 2008) and pro-oxidant properties in others (Ravid et al., 1999). 
Researchers have hypothesized that vitamin D exhibits oxidative properties in some situations 
and pro-oxidant properties in others because vitamin D may actually cause a small amount of 
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oxidative stress, stimulating a cell’s detoxification mechanisms when challenged with other 
oxidative stress challenges (Bao, et al., 2008). More research is needed to test this hypothesis 
rigorously.  
Our study has several limitations that merit discussion. Pre-pregnancy glucose was not 
measured in our study, so we cannot exclude the possibility that a limited number of women may 
have had undiagnosed pre-pregnancy hyperglycemia or type 2 diabetes. Therefore, we cannot 
assert a temporal relationship between vitamin D and maternal hyperglycemia. GDM was rare in 
our cohort and we were not able to study the relationship between vitamin D status and GDM 
diagnosis. However our analysis of continuous glucose allowed us to examine the relationship 
between vitamin D and hyperglycemia across a range of glucose concentrations, even in women 
who were not diagnosed with GDM. We were unable to assess confounding arising from 
physical activity, dietary interventions and water retention as these covariates were not measured 
in our study. Dietary interventions may have improved vitamin D status by improving 
supplementation or increasing dietary intake of foods like fortified milk, and may also decrease 
maternal glucose concentrations through healthy eating and weight control, and this could 
potentially bias our results away from the null. If women had undiagnosed high glucose 
concentrations before pregnancy, this may have affected their kidneys and caused water retention 
(Hryciw, Lee, Pollock, & Poronnik, 2004). This, in turn, may artificially dilute concentrations of 
25(OH)D, making it seem that women with low 25(OH)D concentrations have high glucose 
concentrations, which would also bias our results away from the null. Future studies are needed 
to assess the importance of these potential covariates on the relationship between vitamin D 
status and post-load glucose concentration. However, our study has several strengths. Our 
population was composed of African American and white women and we examined post-load 
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glucose concentration as a continuous variable, a clinically important outcome measure that has 
been associated with adverse pregnancy outcomes. We measured 25(OH)D concentrations early 
pregnancy, which supports a temporal relationship between maternal vitamin D status and 
hyperglycemia. Lastly, we quantified serum 25(OH)D using a DiaSorin RIA kit, a rigorous 
method which detects 100% of 25(OH)D2 and 25(OH)D3.  
Although further research is necessary, we conclude that vitamin D status is positively 
associated with maternal glucose in non-smokers and negatively associated with maternal 
glucose in smokers in this cohort of primarily African American, smoking pregnant women. 
Considering that a vast number of pregnant women are vitamin D insufficient and that rates of 
GDM are increasing, research is urgently needed to better understand of the role vitamin D plays 
in the development of maternal hyperglycemia among smokers and non-smokers. This 
information is needed so that effective interventions to reduce the risk of maternal 
hyperglycemia can be developed.  
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6.6 FIGURES AND TABLES 
 
Figure 8. Univariate relationship and locally weight regression line between early pregnancy 25-
hydroxyvitamin D status and post-load glucose concentration, stratified by smoking status (p < 0.01), N = 484. 
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Table 12. Maternal characteristics of SNAP participants, prevalence of insufficient vitamin D status by 
characteristic, and mean maternal post-load glucose concentration by characteristic, n = 484 
Characteristic N (%) 
25(OH)D≤50 
nmol/L 
N (%) p-value1 
Glucose 
mg/dl 
mean (SD) p-value 
Parity      
     0 102 (21.6) 48 (47.1)  99.2 (22.8)  
     1-7 370 (78.4) 268 (72.4) <0.01 100.0 (25.4) 0.27 
Race/Ethnicity      
     White 181 (37.4) 73 (40.3)  103.9 (25.5)  
     African American 303 (62.6) 252 (83.2) <0.01 96.7 (24.1) <0.01 
Smoking status      
     Smoker 220 (45.5) 144 (65.5)  100.2 (24.8)  
     Non-smoker 264 (54.5) 181 (68.6) 0.47 98.7 (25.0) 0.25 
Marital status      
     Married 71 (14.7) 35 (49.3)  110.2 (25.0)  
     Not married 413 (85.3) 290 (70.2) <0.01 97.5 (24.4) <0.01 
Annual family income      
     < $10,000 207 (43.9) 146 (70.5)  98.2 (23.5)  
     $10,000-25,000 161 (34.1) 115 (71.4)  97.2 (22.8)  
     $25,000-50,000 89 (18.9) 53 (59.6)  106.2 (29.2)  
     ≥ $50,000 15 (3.2) 4 (26.7) <0.01 104.5 (31.0) 0.01 
Employment status      
     Employed 249 (51.5) 168 (67.5)  99.5 (26.2)  
     Not employed 234 (48.5) 156 (66.7) 0.85 99.5 (23.2) 0.88 
Educational status      
     ≤ High school degree 427 (88.2) 294 (68.9)  98.4 (24.6)  
     College degree 47 (9.7) 28 (59.6)  105.1 (25.7)  
     Post-college degree 10 (2.1) 3 (30.0) 0.02 116.4 (25.8) 0.02 
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Family history of diabetes      
     History of diabetes 166 (36.6) 120 (72.3)  99.4 (25.9)  
     No history of diabetes 288 (63.4) 187 (64.9) 0.11 99.8 (24.7) 0.92 
Pre-pregnancy BMI (kg/m2)      
     Underweight (<18.5) 19 (3.9) 9 (47.4)  98.1 (21.5)  
     Normal (18.5-24.9) 188 (38.8) 116 (61.7)  94.8 (24.2)  
     Overweight (25-29.9) 103 (21.3) 65 (63.1)  101.8 (24.0)  
     Obese (≥30) 174 (36.0) 135 (77.6) <0.01 103.0 (25.9) <0.01 
25(OH)D season sample      
     December-May 219 (45.2) 176 (80.4)  99.5 (26.0)  
     June-November 265 (54.8) 149 (56.2) <0.01 99.2 (24.0) 0.92 
25(OH)D = 25-hydroxyvitamin D; BMI = body mass index 
Missing: 12 women missing parity; 12 missing income; 30 missing family history of diabetes 
125(OH)D≤50 nmol/L: χ2 test;  mean glucose: Student’s t-test, Wald test for BMI, income status 
and educational status 
 
Table 12 continued. 
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Table 13. Maternal post-load glucose concentration and GDM prevalence by vitamin D insufficiency, N=484 
Vitamin D status 
Total 
N (%) 
Glucose concentration 
(mg/dl) 
Mean (SD) p-value1 
Glucose ≥ 135 
(mg/dl) 
N (%) p-value 
GDM 
N (%) 
p-value 
25(OH)D < 50 nmol/L 325 (67.1) 98.6 (25.4)  35 (10.8)  9 (2.8)  
25(OH)D ≥ 50 nmol/L 159 (32.9) 101.0 (23.8) 0.32 14 (8.8) 0.50 3 (1.9) 0.56 
GDM = gestational diabetes mellitus 
1Students’ t-test for glucose concentration and χ2 test for glucose ≥ 135 mg/dl and GDM 
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Table 14. Association between early pregnancy (< 16 weeks) vitamin D status and maternal post-load 
glucose concentration, stratified by smoking status, n = 484 
Non-smokers 
Unadjusted 
β (95% CI) 
Adjusted1 
β (95% CI) 
Serum 25(OH)D,  
β reflects 21 nmol/L increase 4.9 (2.0, 7.8) 4.1 (0.9, 7.2) 
Vitamin D status   
     25(OH)D < 50.0 nmol/L ref ref 
     25(OH)D ≥ 50.0 nmol/L 8.8 (2.3, 15.2) 6.9 (0.2, 13.6) 
Smokers   
Serum 25(OH)D,  
β reflects 21 nmol/L increase -7.6 (-11.9, -3.2) -7.3 (-11.4, -3.1) 
Vitamin D status   
     < 50.0 nmol/L ref ref 
     ≥ 50.0 nmol/L -13.8 (-23.2, -4.4) -13.6 (-22.7, -4.5) 
BMI = body mass index; 25(OH)D = 25-hydroxyvitamin D 
1Adjusted for pre-pregnancy BMI, race/ethnicity, maternal age, and 25-hydroxyvitamin D 
sample season 
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7.0  SYNTHESIS 
7.1 OVERVIEW OF RESEARCH FINDINGS 
This dissertation used complementing data from two pregnancy cohorts, the Study of Nutrition 
and Pregnancy (SNAP) and the Antidepressant Use during Pregnancy (ADUP) Study, to 
improve our understanding of the interrelationship of maternal obesity, nutritional status, and 
maternal hyperglycemia, which is defined as high blood sugar during pregnancy (Metzger, et al., 
2008). We established associations between early maternal adiposity measures and 
hyperglycemia. Principle component analysis was used to create nutritional biomarker 
components and these components were used to assess the association between pre-pregnancy 
obesity and maternal micronutrient and EFA status. We also explored the relationship between 
early pregnancy vitamin D status and maternal glucose concentrations. Here we outline the 
research findings presented in this dissertation. 
1) Determine the independent and joint associations between maternal pre-pregnancy 
BMI, GWG, and adiposity distribution at <16 weeks gestation and maternal post-load glucose 
concentrations. 
Measures of post-load glucose concentration and maternal adiposity from SNAP were 
used to assess the association between maternal adiposity and hyperglycemia during pregnancy. 
Patterns of GWG by trimester and GWG adequacy, as well as skinfold thicknesses and waist 
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circumference, were explored as independent variables. We found that high GWG in the first 
trimester, independent of pre-pregnancy BMI, was associated with hyperglycemia later in 
pregnancy. This finding was consistent with other studies that have explored trimester-specific 
GWG in other populations, though ours was the first study to explore this association with 
hyperglycemia in a population of black and white, low-income women. Pregnant women with 
high GWG in their first trimester may have an elevated risk of maternal hyperglycemia because 
early pregnancy weight gain, of which a large part is fat accumulation, may increase biological 
factors that can increase insulin resistance above that of the normal pregnant state. 
We also found that high early pregnancy biceps and triceps skinfold thicknesses, 
measures of subcutaneous fat, were associated with maternal hyperglycemia.  There is a paucity 
of information regarding the role of adiposity distribution in the development of maternal 
hyperglycemia a gap that our results help to ameliorate. However, there is some evidence that 
maternal diabetes and obesity may cause defects in the insulin-signaling pathway in maternal 
subcutaneous adipose tissue. 
2) Using principal component analysis to discover the underlying structure of maternal 
nutritional biomarkers and evaluate the independent effect of general adiposity on these patterns 
at ≤ 20 weeks gestation. 
We used pre-pregnancy BMI and nutritional biomarker data from the ADUP study cohort 
to explore the association between of maternal general adiposity and nutritional (micronutrient, 
carotenoid and EFA) status. Principal component analysis of fifteen nutritional biomarkers 
measured at ≤ 20 weeks gestation was performed to create three nutritional components: a 
Micronutrient component, a Carotenoid component, and an EFA component. Pre-pregnancy 
obesity was associated with the decreased Carotenoid and EFA Components scores. 
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The use of principal component analysis allowed us to explore the relationship between 
maternal adiposity and a wide array of nutritional biomarkers, and also allowed us to take into 
account the inherent correlation between individual nutritional biomarkers. This relationship may 
arise from poor diet quality among obese women or excess fat altering the absorption and 
metabolism of nutrients or creating an increased need for antioxidant nutrients by increasing 
oxidative stress. 
3) Determine the effect of maternal vitamin D status at <16 weeks gestation on maternal 
hyperglycemia.  
We used the SNAP cohort, which had a large percentage of women who smoked during 
pregnancy, to determine the association between maternal 25-hydroxyvitamin D status early in 
pregnancy and maternal hyperglycemia. In non-smokers, 25-hydroxyvitamin D and maternal 
post-load glucose concentrations had a positive, linear association, whereas in smokers, 25-
hydroxyvitamin D and maternal post-load glucose concentrations had a negative, linear 
association. These findings are not consistent with previous literature. Therefore, we confirmed 
our results using biomarker of self-reported smoking status.     
7.2 STRENGTHS AND LIMITATIONS OF THIS RESEARCH 
Our proposed study has limitations that should be taken into account. Our research was 
challenged by small sample sizes and missing data. Because this was a secondary analysis, often 
using data collected outside the research setting, many women in the ADUP and SNAP cohorts 
were missing information on nutritional biomarker status, glucose concentrations or serial 
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measured weights during pregnancy. Our analysis of adiposity distribution was also limited by a 
small sample size because the anthropometric measurements that we used were added to the 
protocol mid-way through the study. As a result, our analytic sample was reduced. Although, 
important variables of interest rarely differed meaningfully between our analytic sample and the 
larger cohort, the reduction in sample size limited the precision of our effect estimates and 
restricted our ability to explore important covariates, such as the interaction between trimester 
specific GWG rates.  
We were unable to use more rigorous measures of adipose tissue, such as dual-emission 
X-ray absorptiometry scans or bioelectrical impedance analysis because they are cumbersome 
and costly. This means that our analysis of adiposity were less accurate than had we used these 
more rigorous methods. Although we took skin fold thicknesses and waist circumference 
measurements three times to reduce random error, anthropometric measurements are particularly 
susceptible to user error. Using anthropometric measurements also impeded our ability to 
differentiate between different kinds of adipose tissue (e.g. fat mass versus fat-free mass). 
Nevertheless, the anthropometric measurements we used could potentially be more applicable in 
a practical clinical setting. Maternal weight at each clinic visit was measured by hospital staff in 
a clinical setting, without a standardized protocol. Our measures of pre-pregnancy BMI were 
calculated using self-reported height and weight, which may lead to misclassification of pre-
pregnancy BMI status.  
An additional limitation was that there is not an available “gold standard” method of 
measuring global nutritional status. The nutritional biomarkers we used may have varied because 
of many factors, such as metabolism and physical well-being. Nutritional biomarkers are 
correlated to a woman’s diet and likely had inter-person variability because a woman’s diet 
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changes from day to day. The nutritional biomarkers that we used generally reflect an average of 
a woman’s micronutrient and EFA concentration over a period of time, but this period of time 
was different between assays. The assay we used to measure vitamin D in the ADUP cohort has 
large inter- and intra-participant variability and may have over-estimated the concentration of 
vitamin D, although our measurements were validated using HPLC in the ADUP cohort.  
Our measure of maternal post-load glucose may also have limitations. Because the SNAP 
cohort population had a low prevalence of GDM, we did not have the sample size necessary to 
conduct an analysis of GDM status. Blood glucose measurements were collected in a clinical 
setting, rather than a research setting. Therefore, they may be subject to measurement error 
because of varying collection techniques and handling of samples, including collecting samples 
across a wide range of gestational ages. Variation in collection and handling of samples is likely 
to be uniform across women and would not differ by anthropometric or vitamin D status. This 
limits the potential for differential misclassification. Gestational age of screening likely differs 
by GDM risk. To mitigate this limitation, we assessed gestational age at screening for 
confounding and conducted sensitivity analysis to assess the effect of including or excluding 
women with early glucose screening, who may have been at higher risk, in our analysis.  
There are several methodological limitations that should be taken into consideration 
when reviewing our results. Both ADUP and SNAP recruited participants on a volunteer basis 
and this may have introduced volunteer bias into results. For example, if women who were 
willing to volunteer for ADUP were more likely to be obese and well-nourished, our results 
would have been biased towards the null. In our analysis of the association between adiposity 
and maternal glucose concentrations, women who were excluded from our analysis were more 
likely to be smokers and nulliparous than women included in the analysis. If non-smoking or 
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multiparous women were more likely to have excess adiposity, and were more likely to develop 
hyperglycemia, then our results would be biased away from the null. Our results may also be 
susceptible to measurement bias. Our measure of GWG was calculated using weights measured 
in a clinical setting without a standard protocol and if clinical staff was more likely to measure 
weights differently in obese women, (e.g. rounding weight measurements of obese women down 
or up, encouraging obese women to remove shoes), then women at high risk for hyperglycemia 
may have an artificially high or low GWG. Women who are obese during pregnancy may also 
systematically recall their pre-pregnancy weight as either higher or lower than their actual 
weight, which may have led to misclassification in our data. Our results may also be affected by 
unmeasured confounding. For example, we were unable to adjust our results for dietary intake, 
supplement use, physical activity, genetic factors and sunlight exposure. Lastly, our study used 
observed data and therefore we can only suggest associations and we cannot suggest causality. 
Despite these limitations, our study also has many advantages. In both SNAP and ADUP, 
our data was prospectively collected. In the SNAP cohort, we were able to assess exposures, i.e. 
adiposity distribution and vitamin D status, early in pregnancy. We were able to analyze 
maternal post-load glucose concentrations as a continuous variable which allowed us to explore 
the linear nature of our associations. Also in the SNAP population, we were able to investigate 
the relationship between adipose and glucose concentrations and vitamin D and glucose 
concentrations in a black and white population. Principal component analysis was used to assess 
nutrition status, allowing us to assess multiple biomarkers, and the correlations between these 
biomarkers, simultaneously. We used biomarkers of micronutrient (including carotenoid) and 
EFA status, which are objective measures of a woman’s nutrient status. The assays used to 
quantify micronutrient and EFA concentrations have intrinsic measurement error and a limit of 
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detection, below which we were unable to determine the micronutrient or EFA concentration of a 
sample. But this limitation, as well as the skewed distributions of the biomarker concentrations, 
was ameliorated by the use of Spearman's rho correlation coefficients in a principal component 
analysis. We were able to contribute new information to the field of adiposity and nutrition, 
modifiable risk factors to prevent the development of maternal hyperglycemia. Lastly, our study 
evaluates relationships of great public health importance. 
7.3 PUBLIC HEALTH SIGNIFICANCE 
The findings of this dissertation have important implications for the improvement of public 
health among pregnant women and their infants. Many women develop GDM during pregnancy, 
and it is likely that even more suffer from maternal hyperglycemia. Both GDM and maternal 
hyperglycemia have been associated with adverse pregnancy and birth outcomes such as 
preeclampsia, macrosomia, and birth trauma. Understanding the factors that may be associated 
with the development of hyperglycemia during pregnancy is important for the formation of 
effective interventions to prevent maternal hyperglycemia. This, in turn, could have a major 
impact on the health of women and their infants. 
The results of this project suggest that there are aspects of adiposity, independent of pre-
pregnancy BMI that may contribute to the development of maternal hyperglycemia. Women who 
have a normal pre-pregnancy BMI, but high levels of subcutaneous fat or GWG early in 
pregnancy may be at high risk for developing maternal hyperglycemia, but misclassified as low 
risk. Maternal adiposity is a modifiable risk factor and screening for high adiposity can be easily 
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accomplished because GWG is typically measured throughout a woman’s prenatal care and 
anthropometric measures of subcutaneous fat can be easily, safely and inexpensively measured 
in a clinical setting. Effective interventions to prevent excessive adiposity in early pregnancy 
may prevent or reduce the prevalence of maternal hyperglycemia, which could considerably 
decrease the burden of disease during pregnancy and delivery. 
Public health can also be improved by the knowledge that women who are obese before 
pregnancy may be a high-risk group for having poor EFA and carotenoid status during 
pregnancy. Pre-pregnancy obesity rates in the United States, much like rates of obesity in non-
pregnant populations, have reached epidemic proportions and are increasing. Insufficient levels 
of carotenoids and EFAs, both essential for a healthy pregnancy and normal fetal development, 
among obese women could be detrimental to maternal and child health. Interventions, for 
example targeted multi-micronutrient supplementation, have been effective in improving the 
nutritional status in other high risk pregnancy populations, and may Nutritional interventions are 
safe, acceptable and effective and targeted nutritional interventions could be developed to 
improve pregnancy and birth outcomes in this at-risk population. 
Our results that vitamin D status is significantly associated with maternal hyperglycemia 
have great public health impact. A fuller understanding of the relationship between maternal 
vitamin D status and glucose concentrations, and the potential interaction between vitamin D and 
the oxidative stress caused by smoking, can be used to develop effective interventions to reduce 
the prevalence of hyperglycemia during pregnancy. A large percentage of pregnant women, for 
example more than 50% in our study, have insufficient levels of vitamin D, and nutritional 
interventions to improve vitamin D status could potentially have a great impact on the number of 
women affected by high glucose concentrations. 
105 
 
This research also has important clinical implications. We found that first trimester GWG 
and subcutaneous fat are associated with maternal glucose concentrations, independent of family 
history of diabetes and pre-pregnancy BMI. If clinicians are using high pre-pregnancy BMI and a 
family history of diabetes as their only identifying criteria for increased hyperglycemia and 
GDM risk, then many at-risk women may be overlooked in early screening and intervention. Our 
results that obese pregnant women may have poorer carotenoid and EFA status may inform 
targeted nutritional interventions that can be easily incorporated into clinical practice. The result 
that vitamin D status is positively associated with maternal glucose in non-smokers and 
negatively associated with maternal glucose in smokers needs to be confirmed with further 
research before these conclusions can be incorporated into clinical practice. But our results do 
suggest that the relationship between vitamin D and glucose may be more complex than 
previously thought.  
7.4 DIRECTIONS FOR FUTURE RESEARCH 
The conclusions of this dissertation can be used to inform the planning of randomized controlled 
trials of weight control early in pregnancy to prevent hyperglycemia and of targeted nutritional 
interventions in obese pregnant women. Additionally, our results that subcutaneous fat may be 
independently associated with maternal glucose concentrations can be used to develop 
investigations of the role adiposity plays in the pathogenesis of maternal hyperglycemia and 
GDM. Lastly, our results revealed a potential new aspect of the relationship between vitamin D 
and maternal glucose concentration: that smoking, perhaps by causing oxidative stress, may 
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modify the effect of this relationship. But the post-hoc nature of our results necessitates further 
study to confirm these conclusions. 
Future studies with larger sample sizes will be able to assess important aspects of this 
research that we were unable to explore due to data collection and time constraints. In a larger 
cohort, researchers will be able to test if trimester of gain modifies the relationship between 
GWG and post-load glucose concentrations. Because composition of maternal weight gain 
differs by trimester, this information is crucial in order to develop timely interventions. Waist 
circumference was only collected in a sub-sample of our cohort and if the effect size of waist 
circumference is small, larger studies would be required to observe this effect. Similarly, our 
estimates of the effect of pre-pregnancy BMI on micronutrient (including carotenoid) and EFA 
status would be more precise with a larger cohort of women with a full array of nutritional 
biomarkers.  
The arena of maternal adiposity, nutrition and maternal hyperglycemia would also benefit 
from studies that include several variables that were not available to us in this study. There are 
more advanced imaging technologies, for example MRI or ultrasounds, which are considered 
safe during pregnancy. These methods will provide more accurate information of adiposity 
quantity and distribution, but are also expensive and cumbersome and do not lend themselves to 
clinical screening interventions. Alternatively, there is a wide array of other inexpensive and 
simple anthropometric techniques that future studies can explore to better understand different 
aspects of maternal adiposity distribution, such as percent of body fat, which we could not 
calculate with the measures at hand. Future studies would also benefit from the collection of 
glucose concentrations before pregnancy so that women with undiagnosed type 2 diabetes can be 
excluded. Lastly, there are many additional covariates that we were unable to measure that are of 
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interest, but the two that we most strongly recommend being included in future research are 
supplement information and physical activity. Both of which are likely to have a considerable 
impact on this research field. Regular supplement use and physical activity are likely to decrease 
obesity, improve nutritional status and decrease the likelihood of developing hyperglycemia. 
Future studies of the role of oxidative stress and its interaction with vitamin D in the 
development of maternal hyperglycemia are warranted. We have suggested that these studies are 
especially important in cohorts with high rates of smoking. Here we were able to conduct a post-
hoc analysis of one measure of oxidative stress, exhaled CO, but there are other markers of 
oxidative stress that may give researchers more information about this relationship. Also, we 
were only able to conduct this analysis in a sub-set of our cohort. 
We also recommend that our results be confirmed in populations at higher risk for GDM. 
For example, cohorts of older women from higher risk racial/ethnic groups. We observed linear 
relationships between maternal post-load glucose concentrations and measures of adiposity and 
vitamin D status in a primarily low risk population. It is important to establish if this relationship 
is similar in higher risk populations. A higher risk population would also allow for an analysis of 
overt GDM as well as maternal hyperglycemia. 
Observational studies provide valuable insights of associations between maternal 
adiposity, nutrition and hyperglycemia, but we cannot assert causality from these studies. To 
truly understand the effect that these factors have on the development of maternal 
hyperglycemia, future researchers must develop effective interventions to improve obesity and 
nutritional status in pregnant women.  Furthermore, these interventions must be tested for their 
ability to prevent and control maternal hyperglycemia. 
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